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Chapter 1
General introduction
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Psychotic disorders probably are the most impressive and disruptive disorders in psychiatry 
among those who suffer from them as well as friends, relatives or other people that come across 
subtle or striking symptoms like delusions or hallucinations. It is therefore not surprising that 
schizophrenia, the ‘prototypic’ psychotic disorder, is the subject of numerous books, movies 
and artwork. Many of these are informative and rightly illustrate symptomatology, course and 
impact of the illness. Many, however, comprise several incorrect prejudices about patients with 
psychotic disorders, such as split personalities, bizarre aggressive behaviours or lack of social 
skills. Nonetheless, they illustrate the complex and enigmatic character of psychoses and stress 
the need for a framework to evaluate and understand psychotic disorders.
1. Psychosis spectrum disorders
Psychosis spectrum disorders are characterized by (a combination of) delusions, hallucinations, 
disorganization, abnormal psychomotor activity and negative symptoms. These five dimen-
sions are the backbone of classification of psychosis spectrum disorders in the widely used 
international classification systems and are used in most scientific research into psychotic 
disorders. The first four dimensions (1.1-1.4) are usually referred to as “positive symptoms”.
1.1 Delusions are fixed ideas that do not correspond with reality and are held on to as absolutely 
true, even in the presence of contradictory evidence. Delusions can be persecutory, but 
also of reference or grandiosity. Delusions are called ‘bizarre’ when impossible and not 
corresponding with cultural background, such as insertion of thoughts or the idea of being 
controlled by an external power.
1.2 Hallucinations are sensory experiences in the absence of an external stimulus and can 
emerge in every modality (e.g. hearing or taste). Hallucinations occur independent of will 
and are vivid and emotion-loaded. To be of psychopathological significance, the sensory 
experiences should occur in the presence of clear conscience. 
1.3 Disorganization of thought and speech can be noticed in or deferred from conversation. 
A dialogue can be complicated by e.g. frequent changes of subject, responses beyond the 
actual question or mere incoherence. Formal thought disorder is diagnosed when severe 
enough to seriously hamper normal communication and should be distinguished from 
language differences.
1.4 Thoroughly disorganized or abnormal psychomotor activity (including catatonia) interferes 
with goal-directed behavior. In catatonia, striking loss of reactivity to the environment is 
seen. It varies from posturing and mutism to smirking and motor excitement. Although 
catatonia is often associated with schizophrenia, it also occurs in severe mood disorders 
or somatic conditions.
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1.5 Negative symptoms are most frequent in schizophrenia and less in other psychosis 
spectrum disorders. Most striking examples of negative symptoms are affective flattening 
and loss of volition. Other examples are social withdrawal, anhedonia and alogia.
2. Classification of psychotic disorders in DSM-5
In 2013, the fifth edition of the Diagnostic and Statistical Manual (DSM)1 was published, 
although its predecessor DSM-IV (1994)2 is still widely used. The chapter Schizophrenia 
spectrum and other psychotic disorders comprises clusters of the above mentioned symptom 
dimensions. In Table 1, psychotic disorders are listed according to DSM-5. Contrary to DSM-
IV, in DSM-5 schizophrenia is not the opening act of the chapter, though it is still considered 
the most severe illness in the psychosis spectrum.
Table 1. Classification of psychotic disorders according to DSM-5
Code1 Classification2 Symptomatology3
301.22 Schizotypal 
personality disorder
Included in the chapter since it is considered part of the 
schizophrenia spectrum, although elaborated in the chapter 
Personality disorders. 
297.1 Delusional disorder Delusions in the absence of other psychotic symptomatology 
during at least one month.
298.8 Brief psychotic 
disorder
One or more positive symptoms, that do not meet criteria for 
schizophrenia and have a duration between 1 day and 1 month 
until full remission.
295.40 Schizophreniform 
disorder
Two or more positive symptoms during at least 1 month, but 
shorter than 6 months. Good prognostic features (e.g. acute 
onset and perplexity) are included as specifier and resemble the 
Leonhardian description of the cycloid psychoses.
295.90 Schizophrenia Symptoms from the schizophreniform disorder with a duration of 
at least 1 month, but with significant functional decline before or 
since the onset of psychotic symptoms during at least 6 months. 
Specifiers included to classify course after one year or more. The 
subtypes from DSM-IV were abandoned, since they were of no 
prognostic value.
295.70 Schizoaffective 
disorder
Can be classified when both criteria for a depressive or 
manic episode and criterion A from schizophrenia are met 
simultaneously during a large part of the index episode, also 
including a period of at least 2 weeks in which delusions or 
hallucinations are present in the absence of mood symptoms. 
Whereas in DSM-IV the schizoaffective disorder was diagnosed 
cross-sectional, in DSM-5 the longitudinal character has been 
given more emphasis to avoid unsustainable classification.
291.9/ 
292.9
Substance- or 
medication-induced 
psychotic disorders
Delusions or hallucinations caused by use of abuse of alcohol, 
drugs or medication.
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Code1 Classification2 Symptomatology3
293.81/ 
293.82
Psychotic disorders 
due to another 
medical condition
Prominent delusions or hallucinations that are the direct 
pathophysiological consequence of a somatic disease.
293.89 Catatonia Contrary to DSM-IV, where it was considered a schizophrenia 
subtype, it is included in DSM-5 as both a specifier (associated 
with another mental disorder) and as a disorder due to another 
medical condition. Catatonia should comprise 3 or more 
symptoms from a total of 12. 
298.8 Other specified 
schizophrenia 
spectrum and other 
psychotic disorder
Clinical presentations that resemble schizophrenia spectrum 
disorders, but do not meet criteria for any of the specific 
disorders, and in which the clinician chooses to specify the 
reasons why (not).
298.9 Unspecified 
schizophrenia and 
other psychotic 
disorder
Comprises presentations that resemble schizophrenia spectrum 
disorders and do not meet criteria for specific disorders, but in 
which the clinician chooses not to specify the reasons why (not), 
because of too little information (e.g. in an emergency room 
setting).
Note. 1 Diagnostic code derived from ICD, 2 Diagnostic category according to DSM-5, 3 Summary of core symptoms, 
inclusion and exclusion criteria
3. Advantages and disadvantages of classification
The development of classification systems, of which DSM is best known and most widely 
used, has worldwide been of great importance for psychiatry. The use of operational criteria 
to establish diagnoses has improved communication between psychiatrists and other (mental) 
health workers, since consensus was established on the basic elements of the disorder. 
Furthermore, by providing a nosological framework, it has promoted research into illness 
concepts across the boundaries of countries, making it possible to share and combine skills 
and knowledge of different countries and settings. For patients, the establishment of certain 
diagnostic classes (e.g., post-traumatic stress disorder, PTSD) has legitimated the burden of 
their mental problems by delineating these as psychiatric disorder, invoking proper use of 
mental health care facilities and/or social services. In the case of PTSD, but also with respect 
to other disorders, evidence based treatment guidelines have been developed to improve 
efficacy of treatment and outcome of disease. Moreover, in a domain as complex as psychiatry, 
a classification system provides a global summary to those who have to deal with known, 
possible or probable mental disorders in other than health care settings, such as policemen, 
lawyers, politicians and welfare workers.
A proper diagnosis should be informative about present and expected symptomatology 
(“what is going on?”), prognosis and expected course (“where are we going?”), but also on 
etiology and pathophysiology (“how and why did we get here?”). Most of the categorical 
labels from psychiatric classification systems such as DSM are at best informative about 
clusters of symptoms at the time of establishing a “diagnosis”, since the categories are based 
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on symptomatology instead of etiology. Despite the fact that many risk factors for psychiatric 
disorders in general have been identified, expectations on course in the short and in the long 
run are hard to establish for individual patients. Diagnoses may alter during the course of 
the disease because of either their limited stability over time or change of definition of the 
diagnostic criteria in subsequent versions of the applied classification system.3 Psychiatrists in 
general accept that classification, though helpful in many ways, is not the same as diagnosing. 
However, the “D” in DSM has led to reification of the categories which in turn has been 
abundantly applied by many authorities responsible for health care costs, insurance, legislation 
and jurisdiction.4,5 Thus, a diagnosis has become not only important for choosing the right 
treatment, but also in many other ways, e.g., to use welfare, to avoid prison or to control 
(mental) health care costs.
4. Schizophrenia spectrum disorders
With respect to psychotic disorders, the general classification divides the spectrum into 
affective and non-affective psychosis, of which the latter are usually divided into schizophrenic 
and non-schizophrenic psychoses. The schizophrenic psychoses are considered to show an 
unfavourable course and prognosis, with gradual but steady decline in cognitive and social 
functioning.
The lifetime incidence of schizophrenia is estimated to be ~1% in developed countries.6 
Genetic studies have shown a heritability varying from 40-70% and a family history of 
schizophrenia has been demonstrated to be the most important risk factor.7 Over the past 
years, substantial evidence has emerged concerning the relevance of gene-environment 
interactions for the onset and course of disease.8,9 Schizophrenia spectrum disorders are 
reported in a variety of genetic disorders associated with copy number variations (CNVs; 
chromosomal microdeletions and microduplications). Best known in this respect are Prader-
Willi syndrome10,11 and 22q11 microdeletion syndrome.12-14
Dopamine is a central neurotransmitter involved in the pathophysiology of hallucinations 
and delusions, whereas glutamate has received special attention in relationship to negative and 
cognitive symptomatology.15-17 
Risk factors for schizophrenia and related psychoses are, apart from genetic burden, 
among others urbanicity, structural brain damage (either hereditary or acquired), abuse of 
cannabis and obstetrical complications.18 Schizophrenia-like psychoses are also observed in a 
variety of organic syndromes, like epilepsy.19-21
Outcome may vary dramatically between patients and it is thought that in ~20% the 
course of the illness is favourable, with full remission of symptoms and preservation of social 
and occupational functioning.1 The remaining patients show a relapsing-remitting or chronic 
Introduction
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course of disease. The presence of so-called atypical symptoms or negative symptomatology 
and the level of social and occupational functioning prior to first psychosis, are thought to 
be indicative for prognosis22 but there are, to date, no objective parameters to predict disease 
course in individual patients. Some propose that the concept of schizophrenia should be 
conceptualized in different dimensions, to prevent aforementioned heterogeneity in patients 
with the same initial diagnosis (that mostly remains unchanged during follow-up). On the 
one hand, it is generally accepted that course and outcome vary between patients with similar 
diagnoses. On the other hand, given the way psychiatric diagnoses are established, it could also 
be argued that patients with different outcomes should instead be regarded as representatives 
of distinct illness entities. 
5. Diagnosis in clinical practice
Psychiatrists are trained in establishing psychiatric diagnoses applying DSM (or other classifi-
cation systems) using all available information in a longitudinal fashion. Since there are 
multiple sources of information, this can be a time consuming process. What makes it even 
more challenging in times of evidence based medicine, is the absence of objective individual 
conclusive tests (e.g., X-ray, blood test). Research into underpinnings of psychiatric illness is 
performed with emphasis on existing classifications, resulting in a great deal of information on 
categorical groups of patients. However, these findings cannot yet be translated into guidelines 
for individual patients. Moreover, since new concepts can only be accepted when “proven”, 
this inward bound research practice seriously hampers innovative research across the current 
boundaries of classification. Schizophrenia might be the best known psychotic disorder, 
but psychoses emerge in many other psychiatric diagnoses. Many questions have remained 
unanswered to date. Where exactly do psychoses emerge? Does structural brain damage result 
in psychosis or vice versa? And how can findings in groups of patients be translated into 
information for individual patients in everyday clinical practice?
Research into psychotic disorders should be focused on further understanding of putative 
pathophysiological mechanisms in order to improve diagnosis and treatment. Neurotrophic 
proteins such as Brain Derived Neurotrophic Protein (BDNF) have been an area of interest 
because of associations of these proteins with neuroplasticity and disease severity.23-25 The 
glutamate hypothesis has gained attention as a valuable extension for the dopamine hypothesis 
to understand the emergence of cognitive symptomatology.26-28 Many biochemical parameters 
have been shown to be altered not only in schizophrenia, but in other psychiatric disorders as 
well. Hypotheses about altered neuroplasticity are not exclusive for DSM-categories, but appear 
to cut across diagnostic boundaries.29-31 Furthermore, not all psychosis concepts to date have 
been incorporated in current classifications. Atypical psychoses, such as the cycloid psychoses 
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as described by Leonhard (1957)32, differ from schizophrenia with respect to symptom profile, 
course and prognosis, but are not included as such in DSM or ICD.33-35
In times of scarce financial resources in general and mental health care, time to establish 
a diagnosis is limited and the focus lies on quick assessment of symptoms in order to achieve a 
categorical diagnosis initiating the corresponding treatment protocol. Diagnostic re-evaluation 
is time consuming and considered not to be cost-effective in the short run. However, in the 
long run, ineffective treatments and long-term use of medication might be prevented when 
re-evaluation would have been done on a regular basis. In general, patients do not present with 
an established DSM label but with psychosis, agitation, mania, anxiety or a combination of 
these. Objective, easily applicable tests that are independent from categorical diagnostic labels 
could be helpful in improving and facilitating the diagnostic process from the first visit on, 
thus providing individual patients with more accurate and personally applicable information 
on what to expect in weeks, months or even years to come.
6. Outline of the thesis
The present studies aim at contributing to the search for individual diagnostic tests for patients 
with psychotic disorders across diagnostic boundaries, that are both informative and easily 
applicable in everyday practice. In subsequent studies patients are assessed by different 
diagnostic methods always also including DSM and/or ICD in order to build upon previous 
research.
In chapter 2, the value of routine screening for CNVs by means of micro-array in patients 
with psychotic disorders is investigated. Chapter 3 introduces a symptom checklist for cycloid 
psychoses according to Leonhard with focus on specific symptomatology. The concept of the 
cycloid psychoses is evaluated for prevalence, discriminating symptoms and concordance with 
current classification systems in a cohort of admitted patients with psychoses. 
The next two chapters describe studies in which the associations between biochemical 
parameters, neuroplasticity and treatment responsiveness in patients with psychosis spectrum 
disorders are determined. Chapter 4 deals with the neurotrophic proteins BDNF and S100B, 
and in chapter 5, the dopamine metabolite homovanillic acid (HVA) is addressed. In chapter 
6, the concept of cycloid psychoses according to Leonhard is elaborated by means of direct 
comparison with DSM-IV schizophrenia on the level of biochemical parameters related to 
neuroplasticity, dopaminergic and glutamatergic neurotransmission. 
Finally, in chapter 7, the most important findings of the presented studies are discussed 
in terms of other concepts regarding psychosis spectrum disorders and clinical management. 
Suggestions for future research are proposed.
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Abstract
With the introduction of new genetic techniques such as genome-wide array comparative 
genomic hybridization, studies on the putative genetic etiology of schizophrenia have focused on 
the detection of copy number variants (CNVs), i.e., microdeletions and/or microduplications, 
that are estimated to be present in up to 3% of patients with schizophrenia. 
In this study, out of a sample of 100 patients with psychotic disorders, 80 were investigated 
by array for the presence of CNVs. The assessment of the severity of psychiatric symptoms 
was performed using standardized instruments and ICD-10 was applied for diagnostic classi-
fication. In three patients, a submicroscopic CNV was demonstrated, one with a loss in 1q21.1 
and two with a gain in 1p13.3 and 7q11.2, respectively.
The association between these or other CNVs and schizophrenia or schizophrenia-like 
psychoses and their clinical implications still remain equivocal. While the CNV affected genes 
may enhance the vulnerability for psychiatric disorders via effects on neuronal architecture, 
these insights have not resulted in major changes in clinical practice as yet. Therefore, genome-
wide array analysis should presently be restricted to those patients in whom psychotic 
symptoms are paired with other signs, particularly dysmorphisms and intellectual impairment.
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N
Vs in psychotic disorders
2Introduction
It has become obvious that the phenotypical presentation of psychotic disorders such as 
schizophrenia is extremely heterogeneous and that their symptoms may comprise the entire 
spectrum of psychopathology with a high interindividual variation.1,2 Although the diagnostic 
boundaries of schizophrenia still remain unclear, the worldwide lifetime prevalence of this 
psychotic disorder is estimated to be 0.5-1%.3 Previous studies have shown a heritability varying 
from 40-70%4, and a family history of schizophrenia has been demonstrated to be the far most 
important risk factor.5,6 Over the past years, substantial evidence has emerged concerning the 
relevance of gene-environment interactions for the onset and course of schizophrenia.7,8
With the ongoing developments in genetic techniques, particularly array-based compa-
rative genomic hybridization analysis, it has become possible to investigate the human genome 
in far greater detail than is possible with routine cytogenetic analysis, leading to the discovery 
of previously undetectable defects.9 These so-called copy number variants (CNVs) are deletions 
or duplications ranging in size from 1 kb to 3 Mb resulting in loss or gain of a DNA segment. 
De novo microdeletions are generally considered of clinical significance and are frequently 
associated with intellectual disability.10 Of these patients, a substantial percentage develops 
symptoms from the affective and/or psychotic cluster after adolescence. Microdeletions 
and duplications may also be causatively involved in patients with normal intelligence and 
psychiatric disorders like schizophrenia11,12 or autism.13,14 In his review, Kirov15 calculated a 
collective rate of 3% of patients with schizophrenia in whom rare deletions in 1q42, 22q11 and 
1q21 and duplications in 16p are found. In the general population, this percentage is estimated 
to be 0.1-1%.16 The explanatory power of CNVs for the pathophysiology of psychiatric disorders 
in general and for their phenotypical presentation, however, still needs to be clarified.17,18
In the present study, genome-wide array analysis was performed in a group of patients 
with carefully diagnosed psychotic disorders in order to detect possible pathogenic CNVs. If 
present, their phenotypical relevance was explored and discussed.
Methods
Patients and assessments
Over a period of 30 months, 100 patients referred to the Vincent van Gogh Institute for 
Psychiatry for treatment of psychotic symptomatology were investigated. Patients with pre-
viously demonstrated cytogenetic aberrations and/or intellectual disability (IQ <70) were 
excluded. According to the medical ethical guidelines, 80 patients gave written informed 
consent and 20 refused further participation (CCMO registration number: NL20469.097.07). 
Assessment of symptomatology and collection of data from history was performed using 
Comprehensive Assessment of Symptoms and History (CASH19), Positive and Negative 
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Syndrome Scale (PANSS20), and Clinical Global Impression Scale (CGI21). Final clinical 
diagnoses were made in a so called LEAD conference.22 Subsequently, patients were classified 
according to ICD-10 criteria.23 The main characteristics of the patients including the 
classification of their psychotic disorders are presented in Table 1. Pictures were taken of all 
patients for evaluation of dysmorphisms by an experienced clinical geneticist (IF). In case 
CNVs were found by array, the patient was examined in detail by the clinical geneticist. 
Genetic analyses
DNA was isolated from an EDTA blood sample and genome-wide array analysis was 
performed with an average resolution of 200 kb using the Affymetrix 250k SNP array platform 
(Affymetrix, Santa Clara, CA, USA) as described previously.24
Table 1. Main characteristics of the patients (n=80)
n %
Male / female 53 / 27 66 / 34
Mean age / range (years) 35.0 / 18-62 
Mean age at onset of psychosis / range (years) 27.1 / 9-61
Mean number of episodes / range 2.8 / 1-15
Diagnoses (ICD-10) n %
- schizophrenia
- schizoaffective disorder
- acute and transient psychotic disorder
- bipolar disorder (psychotic)
- other psychotic disorders
50
6
11
6
7
62.5
7.5
13.8
7.5
8.8
PANSS scores (range) at inclusion
- total score
- positive subscale
- negative subscale
- global subscale
86.1 (46-138)
23.1 (11-37)
19.9 (7-40)
43.0 (22-67)
Mean CGI score (range)
- severity 4.5 (2-7)
 
Results
As Table 1 shows, 50 patients fulfilled the criteria for schizophrenia (F20) and in 11 patients, 
a diagnosis of acute and transient psychotic disorder was made (F23). A diagnosis of 
schizoaffective disorder (F25) was established in six patients whereas in another six, bipolar 
affective disorder, current episode manic with psychotic symptoms, was present (F31.2). In the 
remaining seven patients, various diagnoses were made (F29: n=1; F28: n=2; F22: n=3; F21: 
n=1). All patients received antipsychotic medication according to the hospital standards. 
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2If screening for dysmorphic features suggested a particular monogenetic disorder, specific 
genetic tests were performed. However, no abnormalities were disclosed. In 77 patients, 
microarray analysis did not reveal any abnormalities. In three patients, a submicroscopic 
chromosome imbalance was detected. 
Table 2. Phenotype of the three patients with a potentially pathogenic CNV
patient psychiatric phenotype somatic phenotype ICD-10 diagnosis CNV
A (♀ 61) pananxiety, religious 
delusions, delusions of 
influence, catastrophic 
thoughts, olfactory and 
auditory hallucinations
dysplastic ear 
helices, length and 
head circumference 
<2.5 SD
acute polymorphic 
psychotic disorder 
without symptoms 
of schizophrenia 
3.5 Mb loss  
in 1q21.1
B (♂ 36) pressure of speech, 
misrecognition of 
persons, thought 
incoherence, transient 
visual misinterpretations
no dysmorphisms schizoaffective 
disorder, manic 
type 
375 kb gain  
in 1p13.3
C (♂ 22) delusions of persecution 
and grandiose identity, 
non-affective verbal 
hallucinations about 
himself
no dysmorphisms acute 
schizophrenia-like 
psychotic disorder
1.1 Mb gain  
in 7q11.21q11.22
Patient A presented with a subacute onset of psychotic symptoms (total scores on PANSS 
and CGI-S: 79 and 4, respectively) that remitted within one month after treatment with 2.5mg 
haloperidol. Her history disclosed no major somatic or psychiatric diseases and there was no 
family load with neuropsychiatric or genetic disorders. In her, an interstitial loss of 3.5 Mb in 
1q21.1 comprising 45 genes was found (Figure 1a). Patient B had a history of a mild and short 
lasting psychotic episode one year before admission and did not use any psychotropics. Apart 
from atypical psychotic symptoms, there were mild manic symptoms (total scores on PANSS 
and CGI-S: 78 and 5, respectively). With a treatment regimen comprising risperidone (4mg 
daily) and lithium (1600mg daily), all symptoms gradually resolved within three months. Here, 
a 375 kb interstitial gain was found in band p13 of chromosome 1 encompassing two genes 
(Figure 1b). Patient C had neither a history of any psychiatric or somatic disease nor a family 
load with neuropsychiatric or genetic disorders. Shortly prior to admission he developed 
paranoid psychotic symptoms (total scores on PANSS and CGI-S: 63 and 2, respectively) 
which fully remitted after one month of treatment with risperidone 4mg daily. He had a 
1.1 Mb interstitial gain in 7q11.21q11.22 containing 11 genes (Figures 1c).
It remained unclear whether these CNVs had occurred de novo since in none of the 
patients blood samples of the parents were available for carrier testing. A concise description 
of psychiatric and somatic phenotypes as well as ICD-10 classification is presented in Table 2.
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Figure 1a
Figure 1b
Figure 1c
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2Legend to Figure 1
In the upper panel (i) of each plot (A-C), the log2 test over reference ratio is plotted on the y-axis against the genomic Mb 
position from pter to qter on the respective chromosome represented by the idiogram on the x-axis in the lower part of 
each figure. Each red dot represents the average value for a certain SNP probe. The normal ratio with value 0 is indicated 
by the solid, horizontal blue line. Values for normal ratios range between -0.38 and +0.3. Values outside this range are 
considered abnormal.39 In panel ii, the thick blue line represents the average of ten neighbouring SNP probe values. In 
each figure, the aberrant chromosomal region is indicated by a rectangle that is enlarged in the lower left side of that 
figure. The gene content, 250k SNP array probe coverage, structural variation and segmental duplications of the aberrant 
chromosomal region is shown in the lower right side of the figure (screen shot of the Human March 2006 (hg18) Assembly 
of the UCSC genome browser, http://genome.ucsc.edu/).
In 1a, the interstitial 3.5 Mb loss in 1q21.1 of patient A is shown. In 1b, the interstitial gain in 1p13.3 (375 kb) detected in 
patient B is shown, and in 1c, the 1.1 Mb interstitial gain in 7q11.21q11.22 of patient C is shown.
 
Discussion 
In three out of the 80 patients with psychotic disorders (3.75%), one loss and two gains >250 
kb were detected which is in accordance with the report by Kirov who calculated a collective 
percentage of 3% CNVs in schizophrenia.15 
Apart from the recent report by Maiti et al,25 who found three de novo CNVs (two gains 
and one loss) in 7q11.21 in two families with monozygotic twins discordant for schizophrenia 
in which, however, the breakpoints of these CNVs do not overlap with those in patient C, there 
is virtually no literature on the clinical significance. We recently detected a larger, completely 
overlapping gain of 2.4 Mb in 7q11.21 in a prenatal sample and the healthy father of this foetus 
with congenital diaphragmatic hernia. This makes it less likely that this gain is of clinical 
relevance.
With respect to 1p13.3, only Ohtsuki et al. reported on a possible association with the 
netrin G1 (NTNG1) gene, located at 1p13.3, in Japanese families.26 This does not, however, 
apply to patient B, nor does it clarify his symptom profile. Its relevance is further challenged by 
the detection of an exact similar gain in 1p13.3 (in addition to a pathogenic, de novo duplication 
in 10q) in an intellectually disabled patient without any psychiatric symptoms who inherited 
this gain from his healthy father (unpublished data).
Microdeletions in the 1q21 region have been reported in several genome-wide analyses 
in large populations.27,28 A possible relationship between 1q21 and psychotic symptoms was 
reported by three research groups.29-31 Maiti et al. reported on two de novo CNVs in families 
with monozygotic twins discordant for schizophrenia.25 Several genes are mapped on 1q21, 
such as the KCNN332, NOTCH2NL25, and Connexin 40/50.33 Associations of these specific genes 
with schizophrenia in affected patients so far remain equivocal. 
The results from this relatively small study using genome wide array analysis do not 
differ essentially from the reported large scale studies. It has to be stressed that the commonly 
applied diagnostic categories, derived from the ICD or DSM systems, show no relationship 
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to a specific genetic aetiology. Moreover, a single gene defect never codes for a categorical 
psychiatric disorder, but may lead to a biological dysfunction that has a certain probability to 
be associated with the development of an array of psychiatric symptoms.14,17,18 This can best 
be illustrated by the discovery of the DISC1 gene in one family that was originally thought 
to be causally related to schizophrenia34, but later appeared to be involved in a biochemical 
cascade with consequences for neuronal functions predisposing for psychiatric symptoms 
across diagnostic boundaries.35,36 
Although the CNVs detected in three out of 80 patients are not likely to be primarily 
involved in the evolution of their psychotic disorders, systematic genetic analysis in patients 
may reveal novel recurrent microdeletion syndromes that, however, are nearly always 
accompanied with developmental delay and dysmorphisms, and do not seem to correlate with 
psychiatric symptoms.37,38 The counterpart microduplications in these regions often cause a 
much milder phenotype. 
In conclusion, the results of this and other studies on the presence of CNVs in patients 
with psychotic disorders have not yet lead to a further specification of their pathophysiology 
nor to breakthroughs in clinical strategies. Therefore, while genetic analysis should always be 
considered as part of the diagnostic equipment in neuropsychiatry, the application of genome-
wide array analysis in patients with psychotic disorders is mandatory only in the presence of 
other clinical signs such as facial dysmorphisms or developmental delay, 
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Abstract
Objectives: Cycloid psychoses are characterized by pleiomorphic symptomatology with intra-
phasic bipolarity, a remitting and recurrent course and favourable prognosis. Perris and 
Brockington (P&B, 1981) described the first set of operational criteria that were partly incorpo-
rated in ICD-10. The present study investigates psychopathological profiles according to the 
original descriptions by Leonhard, against the background of the criteria from the prevailing 
international classification systems.
Methods: Eighty patients with psychotic disorders were recruited and assessed with various 
psychometric instruments at baseline and after six weeks of antipsychotic treatment in order 
to investigate the presence of cycloid psychoses according to Leonhard (LCP) and the effect of 
treatment with antipsychotics. The overlap between LCP and DSM-IV Brief Psychotic Disorder 
(BPD), ICD Acute Polymorphic Psychotic Disorder (APP) and P&B criteria was calculated.
Results: Using P&B criteria and a symptom checklist adapted from the original descriptions 
by Leonhard, 14 and 12 cases of cycloid psychosis were identified respectively, reflecting a 
prevalence of 15-18%. Small though significant concordance rates were found between LCP 
and both DSM-BPD and ICD-APP. Concordance between LCP and P&B criteria was also 
significant, but modest. 
Conclusions: This study demonstrates that LCP can be identified in a substantial number of 
patients with psychotic disorders. Cycloid psychoses are not adequately covered in current 
classification systems and criteria. Since they are demonstrated to have a specific psycho-
pathological profile, relapsing course and favourable prognosis, it is advocated to include these 
psychoses in daily differential diagnostic procedures. 
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Introduction
As an independent group, the term ”cycloid psychoses” was first coined by Kleist in 1926.1 
Psychoses with atypical symptoms had been described from the turn of the nineteenth century 
and were termed e.g., ‘bouffées délirantes des dégenerées’2, ‘Degenerationspsychose’3, acute 
schizoaffective psychosis4, ‘degeneratiepsychose’5 and atypical psychosis.6 About two decades 
ago, the psychopathological concepts about this type of psychoses were reviewed in detail by 
Tappe.7
In general, cycloid psychoses present with a (sub)acute onset and a polymorphic and 
shifting symptomatology comprising symptoms from both the schizophrenic and affective 
spectrum. Depending on the subtype, most typical symptoms are rapid mood swings, severe 
anxiety and/or ecstasy, confusional states and psychomotor disturbances.8-11 In the fifties, based 
on the detailed longitudinal analysis of symptom profiles, Leonhard delineated three subtypes: 
anxiety-happiness psychosis, confusion psychosis and motility psychosis.12 Later, Pfuhlmann 
and coworkers found high interrater reliability (Cohen’s kappa: 0.82-0.89) of Leonhard’s 
classification system.13
As to prognosis, cycloid psychoses show a remitting and recurrent course with a favourable 
outcome.14-16 The only study on the pharmacological treatment of cycloid psychoses has 
demonstrated beneficial effects of lithium.17 More recently, some evidence has been obtained 
that, in the acute phase, atypical antipsychotics may be useful.18
Although in 1952 the first edition of the DSM comprised a psychotic disorder with 
atypical symptoms resembling some features of the cycloid psychosis (termed schizophrenic 
reaction, acute undifferentiated type), later versions did not cover this diagnostic category. 
In fact, Kraepelin’s dichotomy increasingly dominated the categorical structure in the 
consecutive editions of the DSM so that in DSM-IV19, only Brief Psychotic Disorder (BPD) and 
Schizophreniform Disorder with specifier ‘With Good Prognostic Features’ partially cover the 
cycloid concept. This development and the increase of the clinical diagnosis of schizoaffective 
disorders resulted in a gradual loss of scientific and clinical interest for the cycloid psychoses. 
Recently, in their scholarly review, Jäger and coworkers stipulated the problematic reliability 
and validity of schizoaffective disorder and hinted at a fundamental reconsideration of the 
current diagnostic concepts of psychosis.20 Similar suggestions were made by the research 
group of García-Andrade.21 Therefore, the cycloid psychosis postulate needs to be revisited, 
particularly given its relevance for clinical practice.
The first set of operational criteria for cycloid psychoses in general was formulated by 
Perris and Brockington22 and subsequently incorporated in the ‘Diagnostic Criteria for 
Functional Psychoses’ of the World Psychiatric Association.23 Starting with the ICD-1024, the 
category acute polymorphic psychotic disorder without/with symptoms of schizophrenia 
(APP) is included that was derived from the Perris and Brockington (P&B) criteria. This 
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category comprises, apart from cycloid psychosis, also the psychotic disorder bouffée délirante, 
used in France as a separate diagnostic category.
Clinical studies in patients with Leonhard’s cycloid psychoses (LCP), using brain 
imaging25 and event related potentials26,27, have demonstrated that, in addition to variability 
in symptomatology, course and prognosis, this class of psychoses is etiologically distinct from 
schizophrenia and bipolar affective disorders.28,29 In rare cases of cycloid psychosis, disturbances 
in amino acid metabolism were observed.30,31 Hereditary factors have been demonstrated to 
play a minor role32,33, whereas environmental factors like maternal first-trimester gestational 
infection and obstetrical complications seem to be of etiological importance.34,35 Cycloid 
psychoses predominate in postpartum psychotic disorders.36,37 
The present study aims at delineating cycloid psychoses according to Leonhard’s original 
descriptions and analyses the diagnostic overlap with P&B as well as with ICD-10 and DSM-IV 
criteria.
Methods
Patient recruitment
All patients were recruited at the Vincent van Gogh Institute for Psychiatry, a large psychiatric 
teaching hospital in the southern part of The Netherlands with a catchment area of ~510.000 
inhabitants. The recruitment period comprised 2.5 years (March 2008-September 2010).
Included were adult patients of both sexes (age range: 18-65 yrs) admitted for psychotic 
symptomatology that warranted treatment with psychotropics. Patients were included before 
the start or in the first week of treatment with psychotropics. In all cases, psychopharmacological 
treatment was performed according to the hospital standards by the responsible ward 
psychiatrist. Excluded were patients with proven genetic syndromes or intellectual disability. 
For this reason, a genetic work-up was performed by a registered clinical geneticist. Also 
excluded were patients with relevant somatic or neurologic diseases and females with post-
partum psychopathology. All patients gave written informed consent following the Dutch 
medical ethical guidelines (CCMO registration number NL20469.097.07).
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Table 1. Symptom checklist for cycloid psychosis (translated by Pfuhlmann  
[adapted from Leonhard, 1990])
Original checklist symptom description Translation
1. Ängstliche Stimmung Anxious mood
2. Angstvorstellungen (Bedrohungsideen, 
ängstliche Beziehungsideen)
Anxious beliefs and delusions (ideas of 
threat, anxious ideas of (self-) reference)
3. Ängstlich hypochondrische Ideen Anxious hypochondriacal ideas
4. Pathetisch-euphorische Stimmung Ecstatic elation
5. Beglückungsideen (altruistischer Charakter) Altruistic ideas of happiness
6. Angst und Euphorie im raschen Wechsel Rapidly changing anxiety and euphoria
7. Selbstopferungsideen Ideas of self-sacrifice
8. Affektkongruente optische 
Sinnestäuschungen (aus Angst oder Ekstase)
Mood congruent optical illusions or 
hallucinations (driven by anxiety or 
ecstasy)
9. Affektkongruente Stimmen (aus Angst oder 
Ekstase heraus)
Mood congruent voices (driven by anxiety 
or ecstasy)
10. Rededrang mit Inköhärenz der Themenwahl Pressure of speech with incoherence of 
thematic choice
11. Beziehungsideen mit Ratlosigkeit und 
Hemmung
Ideas of reference with perplexity and 
thought inhibition
12. Bedeutungsideen bei Ratlosigkeit Ideas of significance in association with 
perplexity
13. Stimmen aus Ratlosigkeit Voices in association with perplexity
14. Denkhemmung Inhibition of thought
15. Ratloser Stupor Confused stupor
16. Flüchtige Personenverkennungen Fleeting misrecognition of persons
17. Psychomotorische Erregung mit vermehrter 
Ausdrucks- u. Reaktivmotorik
Psychomotor excitement with increased 
expressive and reactive movements
18. Starke Ablenkbarkeit durch äußere 
Gegebenheiten
Strong distractability by environmental 
stimuli
19. Sinnlose (“leerlaufende”) motorische Aktivität 
(keine Vielgeschäftigkeit!)
Senseless motor activity (not general 
overactiveness!)
20. Sinnlose motorische Sprachentäusserungen 
(Schreien, Johlen, Wortfetzen)
Senseless motor speech expressions 
(screaming, yelling, syllables)
21. Psychomotorische Verlangsamung Psychomotor slowing
22. Stupor mit starrer Motorik Stupor with stiff posture
Note:
Symptom 1-9:  Anxiety-happiness psychosis
Symptom 10-16:  Confusion psychosis (inhibited/excited pole)
Symptom 17-22:  Motility psychosis (akinetic/hyperkinetic pole)
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During the study period, a total of 194 patients were admitted for evaluation and treatment 
of psychotic symptoms of whom 100 were judged to be eligible for inclusion. Twenty patients 
refused to participate yielding a study group of 80 patients of whom 63 were available for 
follow-up assessment (i.e., 63% of the initial selected group). 
Diagnostic procedures and scoring instruments
Baseline diagnostic instruments comprised Comprehensive Assessment of Symptoms and 
History (CASH)38, Positive and Negative Syndrome Scale (PANSS)39, and Clinical Global 
Impression scales for Severity and Improvement (CGI-S/CGI-I).40 The CASH was specifically 
developed for research in the schizophrenia and affective spectrum conditions and is not 
uniquely connected to a classification system. PANSS and CGI were re-assessed at week 6. 
These assessments were performed by a well-trained PhD resident in psychiatry (NvdK).
Subsequently, classification was performed according to DSM-IV19 and ICD-1024 by 
NvdK and FvdH. Independently, the criteria for cycloid psychoses as advanced by Perris and 
Brockington23 were applied to all subjects by a psychiatrist specifically trained in the diagnosis 
of cycloid psychosis (MS). In addition, using the symptom checklist of Leonhard12,41 (Table1), 
an internationally recognized psychiatrist (GS) delineated patients with LCP. Accordingly, a 
division into the three subtypes of cycloid psychosis was performed. 
Analogous to a so called LEAD consensus conference42, in a final meeting with all investi-
gators chaired by an independent experienced psychiatrist (WV), all available classificatory 
data were discussed to analyse the differential application of the various sets of criteria.
Statistics
For all statistic procedures, SPSS 14.0 software was used. Group differences were tested using 
the Student’s t-test for continuous variables and Chi-square test for nominal variables. Cohen’s 
kappa was used to test the concordance between the different categorical diagnostic groups. 
Significance was tested against p<0.05. 
Results
1. Total patient sample and symptomatic reduction after 6 weeks
The total group comprised 53 males and 27 females (mean age ± SD: 35 ± 11.5). Mean age 
at first episode and mean duration of psychotic disease were 27.4 ± 10.7 and 7.6 ± 7.9 years 
respectively. According to DSM-IV, 48 patients met the criteria for Schizophrenia. The 
remaining 32 patients fulfilled diagnostic criteria for Brief Psychotic Disorder: n=10, Psychotic 
Disorder NOS: n=7; Bipolar Disorder: n=7; Schizoaffective Disorder: n=5; Delusional 
Disorder: n=2; and Schizotypal Disorder: n=1.
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Patients were treated with classical/first generation (n=27) and atypical/second generation 
(n=61) antipsychotics, either as monotherapy (n=72) or in combination (n=8). After six weeks 
of treatment, scores on the PANSS total, positive, negative and global scales decreased from 
86 to 69 (20%), 23 to 17 (26%), 20 to 17 (15%) and 43 to 35 (19%) respectively. The CGI-S 
improved from 4.5 to 3.4 (23%). All comparisons were statistically significant (p<0.001).
Table 2. Core symptomatology in patients with cycloid psychosis (Leonhard, 2003)
no sex/age signs and symptoms Leonhard diagnosis
1 ♀, 27 fear of death, suspicion, suspicious anxiety, mood 
congruent imperative voices with aggressive behaviour 
towards mother
anxiety psychosis
2 ♂, 39 mutism, stupor, no spontaneous action, bad self-care, 
severe akinetic symptoms, reduced thinking
motility psychosis, 
akinetic pole
3 ♀, 35 moving and removing things, elated mood, non-goal 
directed psychomotor activity, sleep disturbances, 
paranoid ideation, angry outbursts
motility psychosis, 
hyperkinetic pole
4 ♂, 36 pananxiety, religious delusions, anxious stupor, 
perseveration, verbigeration
anxiety psychosis
5 ♀, 53 anxiety and dysphoria, behaviour driven by suspicion, 
mood congruent delusions of guilt, mood swings, 
transient auditory, tactile and olfactory hallucinations
anxiety psychosis
6 ♂, 39 illogical thinking, higher awareness of meaning, visual 
misinterpretations, delusions of reference
confusion psychosis
7 ♂, 36 delusion of grandiosity, pressure of speech, poor 
concentration, visual misinterpretations, psychomotor 
agitation, chaotic behaviour
confusion psychosis
8 ♂, 47 anxiety, religious delusions, pressure of speech, 
emotionally driven behaviour, illogical thinking
anxiety-happiness 
psychosis
9 ♀, 33 chaotic thinking, auditory hallucinations, mood swings, 
inadequate behaviour
confusion psychosis 
(inhibited pole)
10 ♀, 61 anxiety-driven behaviour, catastrophic thinking, illogical 
speech, delusions of persecution and control, mood 
swings
anxiety-happiness 
psychosis
11 ♀, 46 chaotic and inhibited, confusion, ritualistic behaviour, 
perseveration, disorganised speech, paranoia
motility psychosis
12 ♀, 56 psychomotor agitation, sleep disturbances, delusions of 
reference and grandiosity, chaotic thinking
motility psychosis
2. Diagnosis of cycloid psychoses according to Leonhard and P&B criteria
Concerning cycloid psychosis according to P&B, 14 patients (18%) met the criteria. According 
to Leonhard’s descriptions, in 12 patients a cycloid psychosis was present reflecting a prevalence 
of 15%. Leonhard’s cycloid psychoses could further be specified as anxiety-happiness psychosis 
(n=5), confusion psychosis (n=3) or motility psychosis (n=4). Brief case vignettes are depicted 
in Table 2. Of the 14 patients with P&B cycloid psychoses, 9 also accorded with Leonhard’s 
descriptions (Table 2: no 1-4, 6-9, and 11).
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Table 3. Clinical characteristics of the sample (n=80); Leonhard cycloid psychosis (LCP) versus  
non-cycloid psychosis (Non-CP) 
LCP (n=12) Non-CP (n=68)
Demographics
Male/female ratio
Age, years (mean ±SD)*
Age at onset general symptoms (mean ±SD)**
Age at onset psychosis (mean ±SD)**
Number of episodes (mean ±SD)
PANSS total score baseline
PANSS total score after 6 weeks**
5/7
42.8 (±10.5)
31.8 (±12.6)
38.2 (±11.2)
2.2 (±1.5)
77
55
48/20
33.1 (±11.2)
20.9 (±10.8)
25.5 (±9.5)
2.9 (±2.8)
88
72
DSM-IV diagnoses
- Schizophrenia
- Schizoaffective disorder
- Bipolar disorder
- Brief psychotic disorder
- Psychotic disorder NOS
- Delusional disorder
- Schizotypal disorder
0
2
2
7
1
0
0
48
3
5
3
6
2
1
ICD-10 diagnoses
- Schizophrenia
- Schizoaffective disorder
- Bipolar disorder
- Acute and transient psychotic disorder 1
- Psychotic disorder NOS
- Persistent delusional disorder
- Schizotypal disorder
0
4
1
7 (4)
0
0
0
50
2
5
4 (3)
3
3
1
Meeting Perris & Brockington criteria for cycloid psychosis 9 5
Antipsychotic treatment
- Classical agents
- Atypical agents
- Combination of antipsychotic agents
2
10
0
17
43
8
* Difference between LCP and Non-CP cases, p<0.05. ** Difference between LCP and Non-CP cases, p<0.01. 1 Any F23 
diagnosis, including acute schizophrenia-like disorder. The numbers of patients meeting criteria for Acute Polymorphic 
Psychosis (APP; F23.0/F23.1) are inserted between brackets.
In Table 3, the main characteristics of the non-cycloid (n=68) and LCP (n=12) patient 
groups with their corresponding DSM-IV, ICD-10 and P&B diagnoses are presented. As can be 
inferred, the LCP subgroup has a higher age at onset of both psychosis and general psychiatric 
symptoms. LCP as well as non-CP groups show diagnostic heterogeneity, albeit that a diagnosis 
of schizophrenia, according to ICD and DSM, is exclusively made in the non-CP group. In the 
LCP group, diagnoses of DSM-IV Brief Psychotic Disorder or ICD-10 Acute and Transient 
Psychotic Disorder are represented more often. 
With respect to severity of symptomatology as assessed with the PANSS, total scores 
at baseline did not reveal differences between the two groups. After 6 weeks of treatment 
with antipsychotics in a naturalistic setting, however, the symptomatic decrease was more 
pronounced in the cycloid group (p<0.01).
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3. Psychopathology
Detailed analysis of the individual symptomatology of the LCP patients (n=12) and those who 
met the P&B criteria (n=14), revealed that the seven symptoms ‘ecstatic elation’, ‘altruistic ideas 
of happiness’, ‘rapidly changing anxiety and euphoria’, ‘pressure of speech with incoherence 
of thematic choice’, ‘confused stupor’, ‘psychomotor excitement with increased expressive and 
reactive movements’ and ‘stupor with stiff posture’ (Table 1, symptom checklist items 4-6, 10, 
15, 17 and 22) are most prevalent in both or either group of patients, indicating that bipolarity 
of mood, thought and locomotion, frequently occurring also intraphasic, are key symptoms 
of cycloid psychosis. Moreover, these key symptoms are virtually identical to those from the 
extreme poles as originally described by Leonhard. 
Table 4. Frequency distribution of Perris & Brockington criteria in Leonhard cycloid psychosis (LCP) 
and non-cycloid psychosis (Non-CP)
LCP (n=12) Non-CP (n=68) p
Perris & Brockington criteria n % n % χ²
Perplexity
Ecstatic feelings
Akinesia or hyperkinesia
Mood-incongruent delusions
11
6
8
12
91.7
50.0
66.7
100
12
14
15
64
17.6
20.6
22.1
94.1
<0.001
0.030
0.002
n.s.
Hallucinations
Pananxiety
Concern with death
Mood swings
12
9
4
6
100
75.0
33.3
50.0
56
20
10
20
82.4
29.4
14.7
29.4
n.s.
0.002
n.s.
n.s.
Acute onset 12 100 8 11.8 <0.001
Table 4 illustrates the symptom profile of the 12 patients with LCP as compared to the group 
of non-cycloid psychosis (n=68) by applying the P&B criteria. Whereas delusions and halluci-
nations are present in most of the patients in both groups, the atypical symptoms (perplexity, 
ecstatic feelings, motility disorders and pananxiety) are overrepresented in the LCP subgroup.
4. Cycloid psychosis: representation in ICD/DSM and concordance rates
Concordance rates were calculated for LCP (n= 12) and the most frequent DSM-IV and ICD-
10 diagnoses in this group (see: Table 3). Between LCP on the one hand and DSM-BPD and 
ICD-APP on the other hand a concordance rate of 0.58 and 0.35 (both p≤0.001) was present 
respectively (Figure 1a,b). A concordance rate of 0.63 (p<0.001) was calculated between LCP 
diagnosis according to Leonhard’s symptom checklist and P&B criteria whereas a rate of 0.38 
(p<0.001) was found between LCP and ICD schizoaffective disorder (SAD) (Figure 1c,d). The 
concordance between LCP and DSM-SAD did not reach statistical significance.
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Figure 1a-1d. Concordance rates
1 
Figure 1a-1d. Concordance rates 
1a. 
       Cohen’s Kappa 0.58 (p<0.001)
1b.
       Cohen’s Kappa 0.35 (p=0.001) 
1c. 
       Cohen’s Kappa 0.63 (p<0.001)
1d.
       Cohen’s Kappa 0.38 (p<0.001)
LCP
8
4
DSM-BPD     3
LCP
5
7
ICD-APP  3
LCP
3
9
P&B 5
LCP
8
4
ICD-SAD 2
Legend to Figure 1.
Concordance between Leonhard’s cycloid psychosis (LCP, n=12) and a: DSM-IV Brief Psychotic Disorder (DSM-BPD, n=10), 
b: ICD-10 acute polymorphic psychotic disorder (APP, n=7), c: Perris and Brockington criteria (P&B, n=14) and d: ICD-10 
schizoaffective disorder (ICD-SAD, n=6).
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Discussion
In this observational study with a group of patients admitted for psychotic disorders, the 
presence of cycloid psychoses according to both Leonhard’s descriptions and the criteria as 
established by Perris and Brockington, was investigated. A prevalence rate of 15% was found for 
Leonhard’s cycloid psychoses (LCP). It appeared that cycloid psychosis can also be diagnosed 
according to the P&B criteria, whereas application of Leonhard’s descriptions additionally 
provides differentiation in the three subtypes 
The highest concordance was calculated between LCP and P&B, whereas lower concor-
dance rates emerged between LCP and the different ICD-10 (APP and SAD) and DSM-IV 
(BPD) categories (Figure 1a-d).
With respect to the prevalence of cycloid psychosis, the here observed frequency of 
15% is in accordance with that reported by other investigators (8-24%).14,43-46 The prevalence 
from this study may, however, be biased negatively since female patients with postpartum 
psychopathology were a priori excluded and the sample size was limited due to the strict 
inclusion criteria as defined by the Dutch ethical rules for genetic work-up and for patients 
admitted under a legal act. Still, the overrepresentation of female patients in our cycloid group 
is in line with the results from other studies.11,14,47
Since the majority of the patients who were diagnosed as LCP were classified as ICD-
10 APP or DSM-IV BPD, the concordance rates between these categories are most relevant 
(Figure 1a,b). Albeit that the observed values are higher than those reported by Pillmann and 
coworkers47 with ICD-10 Acute and Transient Psychotic Disorders (including APP) of 0.36 and 
by Van der Heijden and coworkers46 with 0.24 for BPD and 0.31 for APP, it has to be underlined 
that in the latter studies, patients were classified according to P&B criteria only. This suggests 
that the criteria for DSM-BPD and ICD-APP do neither cover sufficiently the descriptions by 
Leonhard nor the P&B criteria and that particularly Leonhard’s symptom checklist is most 
promising for clinical practice. It has to be stressed, however, that this study is the first to 
systematically investigate this checklist in its relation to classification systems and thus needs 
further scientific evaluation.
The observed discrepancies in overlap between LCP and both ICD-APP and DSM-
BPD may be explained by the duration criterion. In DSM-IV as well as ICD-10, a maximum 
duration of 1 to 3 months is required which excludes a priori the cycloid psychoses that are 
characterized by highly variable duration and frequently relapsing course.18,35,48-51
As can be inferred from Figure 1c, the concordance rate between LCP and P&B is also 
rather moderate which may be due to the onset and age criteria, in that the onset criterion in 
P&B comprises a time interval of hours to days, while in LCP this is not quantified. Moreover, 
in P&B the criterion age is restricted to the range 15-50 years, while according to the original 
monograph, LCP does not comprise any age limitation. That three LCP cases are discordant 
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with P&B cycloid psychosis, is explained by the age criterion (>50 years old at first presentation; 
n=2) or the required number of symptoms (≥4; n=1). With respect to the overlap between LCP 
and SAD, it has to be stressed that this finding is rather irrelevant since the SAD as included 
in the ICD-10 and DSM-IV cannot be compared with the acute schizoaffective psychosis 
as originally described by Kasanin4 and is not clearly demarcated from schizophrenia and 
affective disorders.20
As demonstrated in the present study, the three subtypes of cycloid psychosis can clearly 
be discriminated from other psychotic disorders by their pronounced symptomatological 
presentation and intraphasic bipolarity (Table 1). Key features of their core syndromes 
include perplexity, pananxiety, motor disturbances, mood swings and transient hallucinatory 
experiences of any kind.
Interestingly, in the cycloid psychosis group a higher symptom reduction was found after 
6 weeks on antipsychotics from various classes. Although not the main target of the present 
investigation, the pharmacological maintenance treatment of cycloid psychoses is suggested to 
be primarily with mood stabilizers17,52 whereas in the acute phase atypical antipsychotics may 
be beneficial.18 Generally, these psychoses have a good prognosis15,35,48,53 and their diagnostic 
stability is high.54,55
In conclusion, the results demonstrate that the concept of cycloid psychosis is still clinically 
useful and valid. It would therefore be wise to include a separate group of nonaffective acute 
psychoses in the future editions of current international classification systems. Such a proposal 
was recently also formulated by Nugent and coworkers.56 Given the rather high prevalence 
of this kind of psychosis, further clinical studies with differential assessment methods such 
as Leonhard’s symptom checklist are warranted and should particularly focus on treatment 
strategies and long term outcome.
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Abstract
Objective: Brain-derived Neurotrophic Factor (BDNF) and S100B are involved in brain 
plasticity processes and their serum levels have been demonstrated to be altered in patients 
with psychoses. This study aimed to identify subgroups of patients with psychotic disorders 
across diagnostic boundaries that show a specific symptom profile or response to treatment 
with antipsychotics, by measuring serum levels of BDNF and S100B.
Methods: The study sample consisted of 58 patients with DSM-IV psychotic disorders. CASH, 
PANSS and CGI-S/CGI-I were applied at baseline and after 6 weeks of antipsychotic treatment. 
At both time points, serum levels of BDNF and S100B were measured and compared to a 
matched control sample. 
Results: Baseline BDNF and S100B levels were significantly lower in patients as compared 
to controls and did not change significantly during treatment. Dividing the patient sample 
according to baseline biochemical parameters (low and high 25% and middle 50%), no 
differences in symptom profiles or outcome were found with respect to BDNF. However, 
the subgroups with low and high S100B levels had higher PANSS scores than the middle 
subgroup. In addition, the high subgroup still showed significantly more negative symptoms 
after treatment, while the low subgroup showed more positive symptoms compared to the 
other subgroups. 
Conclusion: Serum levels of BDNF and S100B are lowered in patients with psychotic disorders 
across diagnostic boundaries. The differences between high and low S100B subgroups suggest 
a relationship between S100B, symptom dimensions and treatment response, irrespective of 
diagnostic categories.
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Introduction
Since the concept of schizophrenia was formulated by Kraepelin and Bleuler, there is an ongoing 
debate on the etiological and pathophysiological factors of psychoses. Over the past decades, 
increasing evidence has emerged that the prototypic psychotic disorder, schizophrenia, has to 
be considered as a progressive, neurodevelopmental disorder.1,2 
The neurodevelopmental trajectory of the human brain is characterised by an increase 
in grey matter during early childhood and a subsequent decrease during puberty, which can 
be attributed to a process called ‘synaptic pruning’.3,4 Exaggerated synaptic pruning has been 
associated with very early onset of first psychotic symptoms.5 Accordingly, adult patients with 
schizophrenic psychoses show excessive grey matter loss that is paralleled by white matter 
increase in the first and second decade of their illness.6 It has been postulated, that this 
excessive synaptic pruning leads to reduced synaptic connectedness (‘connectivity’) which 
enhances the susceptibility to develop schizophrenia and related psychoses.7 Connectivity can 
be established indirectly by measuring neurotrophic factors involved in the development and 
maintenance (‘plasticity’) of the central nervous system (CNS).8 Some of these neurotrophic 
factors like Brain Derived Neurotrophic Factor (BDNF) and S100B, that both pass the blood 
brain barrier9,10 and of which the peripheral levels correlate well with those in the CNS, have 
been extensively investigated in psychotic disorders.11-14 
BDNF is the most abundant neurotrophic factor in the brain and plays a crucial role in 
develop ment, proliferation, regeneration, survival and maintenance of neuronal function of the 
CNS.15,16 Serum BDNF levels have repeatedly been reported to be decreased in first-episode and 
chronic schizophrenia.17,18 Consistent associations between BDNF levels and symptom profile of 
psychotic disorders, however, have not been found as yet19,20, whereas the results about the effects 
of class or dosage of antipsychotics on the serum concentration of BDNF are very contradictory.21,22
S100B is a calcium-binding protein involved in intracellular energy metabolism in the 
CNS. Depending on the concentration, its extracellular effect is either trophic or toxic. In 
nanomolar concentrations, S100B stimulates neurite outgrowth and enhances survival of 
neurons during development and after injury. In micromolar concentrations, however, it 
induces apoptosis.23,24 With respect to schizophrenia, enhanced levels of S100B and a positive 
correlation with negative symptoms are repeatedly reported.25-27 Treatment with antipsychotics 
over a relatively short period of time has been shown to normalize S100B serum levels.28,29 
In addition, some evidence is available suggesting a relationship between S100B levels and 
neurocognitive parameters30 as well as severity of symptoms.13
Thus, serum concentrations of these two neurotrophic proteins express to some extent 
the functional status of the brain, particularly its neuroplasticity. Moreover, circumstantial 
evidence is available that their concentrations correlate with either severity of symptomatology 
or symptomatic changes during antipsychotic treatment. 
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Aims of the study: The present study was designed to investigate whether the neurotrophic 
proteins BDNF and S100B may be biomarkers for the identification of a specific symptom 
profile or responsiveness to treatment in patients with psychotic disorders irrespective of their 
classificatory status.
Materials and methods
Patient recruitment
Patients were recruited over a period of 30 months at the Vincent van Gogh Institute for 
Psychiatry, a large psychiatric teaching hospital in the South of the Netherlands. The study was 
performed according to the Dutch medical ethical guidelines (CCMO registration number 
NL20469.097.07), approved by the Board of Directors of the hospital and in full accordance 
with the Helsinki Declaration. 
All patients provided written informed consent before entering the study. Included were 
adult patients (male/female, age range 18-65 years) admitted for psychotic symptomatology, for 
which pharmacological intervention with antipsychotics was warranted. As exclusion criteria 
served: proven genetic syndrome, intellectual disabilities and relevant somatic or neurologic 
diseases. Patients unable to provide informed consent were also excluded.
During the study period, a total of 194 patients were admitted and subsequently screened 
for eligibility. Because of severity of psychotic illness, 71 patients had to be excluded for 
informed consent whereas 23 did not meet the inclusion criteria. From the remaining 100 
patients, 20 refused to participate, yielding a study population of 80 subjects of whom 58 
completed the study period of 6 weeks. The latter group (n=58) was included in the analyses. 
Treatment process and diagnostic procedures
All patients were treated with first- or second-generation antipsychotic agents during the study 
period. Pharmacological interventions were performed by the treating psychiatrist according 
to hospital standards. At baseline, the Comprehensive Assessment of Symptoms and History 
(CASH)31 was applied from which classification according to DSM-IV was done. Severity 
and distribution of symptomatology were assessed at baseline and after 6 weeks of treatment 
by means of the Positive and Negative Syndrome Scale (PANSS)32 and the Clinical Global 
Impression scale for severity and improvement (CGI-S/CGI-I).33 
Biochemical assessments
Patients: At both time points of clinical assessment, blood samples were collected to measure 
serum levels of BDNF and S100B. Sampling was performed between 8 and 10 a.m. and serum 
was stored at -80°C until analysis. BDNF was measured by a double antibody sandwich enzyme 
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linked immunosorbent assay (ELISA; Promega, Madison, Wisconsin, USA) and S100B levels 
by a two-site one step ELISA (Sangtec, Bromma, Sweden).
Controls: BDNF and S100B levels of control subjects were extracted from a database of 
the neuropsychiatric laboratory of Erasmus Medical Centre (EMC) comprising data from staff 
members and students of the EMC and subjects from the general community. None of the 
control subjects neither their first degree relatives had a history of psychiatric illness. For the 
S100B assay, control subjects were matched for both age and gender. Since we could not find 
any correlation between BDNF and age in our control group (50 men and 25 women, age 
27.5 ± 6.8 years; p=0.908), for the BDNF assay control subjects were matched for gender only. 
Consequently, separate control groups were created for BDNF (n=75) and S100B (n=77). 
Statistics
The Student’s t-test was used for normally distributed variables (PANSS scores), the Mann-
Whitney U test was used for non-normally distributed variables (BDNF/S100B serum levels) 
and a Chi-square test was used for binary variables. A paired t-test (PANSS total and subscales) 
or Wilcoxon’s Signed Rank test (BDNF/S100B serum levels) was used to analyse changes 
between time points. The Kendall tau test was used to establish correlations between BDNF/
S100B serum levels and clinical variables. Between-group differences were determined by 
univariate analysis of (co)variance (AN(C)OVA). All analyses were two-tailed. Significance 
was set at p<0.05. Data are presented as mean +/-SD, unless stated otherwise.
Results
Patient characteristics
The main characteristics of the 58 patients that completed the study are outlined in Table 1. 
Mean duration of psychotic illness was 8.1 (±8.4) years. According to DSM-IV, 33 patients were 
classified as schizophrenia whereas in the remaining 25 patients various diagnoses from the 
schizophrenia spectrum were made. Eighteen patients were free from psychotropics at least 
2 weeks prior to study entry. Duration of treatment in the medicated patients varied from 2 
weeks to >10 years. 
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Table 1. Patient characteristics at baseline (n=58)
Gender (male/female)
Age (mean ±SD)
38/20 (66/34%)
36.7 ± 11.7 years
Age at first psychosis, years (mean ±SD)
Duration of psychotic illness, years (mean ±SD)
28.5 ± 11.1
8.1 ± 8.4
Diagnosis (DSM-IV) Schizophrenia (n=33)
Schizoaffective disorder(n=2)
Brief psychotic disorder (n=8)
Bipolar disorder (n=7) *
Psychotic disorder NOS (n=6)
Delusional disorder (n=1)
Schizotypal personality disorder (n=1)
Smoking yes/no
Hard drugs in month prior to study entry yes/no
Soft drugs in month prior to study entry yes/no
38/20 (66/34%)
2/56 (3/97%)
10/48 (17/83%)
Medication status at study entry Naïve (n=10)
Free >2 weeks (n=8)
Using medication (n=40)
Medication used at study entry ** 1 AP (n=15)
1 MS (n=5)
2 AP (n=6)
AP + AD (n=6)
AP+MS+AD (n=2)
AP+MS (n=2)
2 AP + AD (n=2)
* manic episode with psychotic features
** AP: antipsychotic agent (any), MS: mood stabilizer (any), AD: antidepressant (any)
Clinical and biochemical treatment effects
Clinical and biochemical parameters of the patients are outlined in Table 2. As reflected by the 
score on the CGI-S the study group was ‘moderately to markedly ill’ (score 4.4). Concerning 
treatment efficacy, a mean reduction of 20% (p<0.001) on the PANSS total score was noted, 
corresponding with the generally used definition of ‘response’. Reductions on PANSS positive, 
negative and global scores were 24%, 14% and 18%, respectively (all p<0.001). On the CGI-S, 
a mean reduction of 23% was noticed.
The mean serum levels of BDNF and S100B were significantly lower as compared to 
controls (BDNF: 20.3 ± 6.6 versus 24.4 ± 6.7 μg/l, p≤0.001; S100B: 0.063 ± 0.032 versus 0.069 
± 0.029 μg/l, p<0.05). With respect to BDNF, mean age of the patients was higher compared to 
control subjects (36.7 ± 11.7 and 27.5 ± 6.8 years, p<0.001). However, this age difference did 
not result in differences in serum BDNF levels, since there was no correlation between age and 
BDNF levels in the study sample at both time points (the non-parametric Kendall’s Tau test 
showed p-values of 0.143 and 0.323, respectively). Moreover, the laboratory involved found no 
correlation between age and BDNF levels in healthy subjects (n=75, p=0.908). Serum levels of 
BDNF and S100B did not change significantly during 6 weeks of treatment with antipsychotics.
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Possible confounding factors
Since several factors could possibly influence serum levels of neurotrophic proteins, data were 
scrutinized for effects of smoking, body mass index, abuse of soft or hard drugs, medi cation 
status (naïve, free >2 weeks or medicated), antipsychotic class (first- or second-generation agent), 
co-medication (antidepressants or mood stabilizers), diagnostic category (schizophrenic or 
non-schizophrenic psychoses), gender and age. 
Baseline BDNF levels were significantly lower in medication naïve patients as compared to 
medication-free and medicated patients (15.4 ± 6.6, 20.6 ± 5.6 and 21.5 ± 6.5 μg/L respectively, 
p=0.022). In addition, serum levels of S100B were positively correlated with age at both time 
points (Kendall’s Tau 0.197 and 0.212 respectively, p<0.05). Moreover, patients who had used 
soft drugs before study entry (n=10) had significantly lower levels of S100B after six weeks 
of treatment (0.067 ± 0.033 versus 0.042 ± 0.015). Finally, neither of the other parameters, 
especially gender, diagnostic category and co-medication, were found to have any influence 
on serum levels of either neurotrophic protein. For all analyses of BDNF and S100B values, 
medication status respectively age and use of soft drugs, were used as covariates.
Sample division according to baseline biochemical parameters
No correlations were established between BDNF and S100B levels on one hand and PANSS 
scores on the other hand at both time points in the total patient sample (Kendall’s Tau, all 
p>0.05). In order to detect possible differences in symptom profile or symptomatic improvement 
between patients with high and low levels of neurotrophic proteins, the sample was divided 
into three subgroups (lowest quarter [L-BDNF/S100B], highest quarter [H-BDNF/S100B], and 
middle group [M-BDNF/S100B]). After analysis, all factors that might influence PANSS scores 
(see: possible confounding factors) appeared to be equally distributed between the BDNF 
and S100B subgroups demonstrating that they could not have influenced any of the outcome 
measures. At baseline, mean levels of BDNF and S100B varied significantly from each other. 
All differences remained significant during the study period (BDNF: 12.9 ± 2.3 (at baseline) 
and 12.8 ± 4.9 (after treatment) [L: n=14], 19.4 ± 2.5 and 19.9 ± 4.6 [M: n=30], 29.7 ± 4.1 and 
25.5 ± 6.3 μg/L [H: n=14]; S100B: 0.034 ± 0.005 and 0.044 ± 0.011 [L: n=14], 0.054 ± 0.009 and 
0.058 ± 0.025 [M: n=29], 0.107 ± 0.030 and 0.088 ± 0.041 μg/L [H: n=15], all p≤0.001).
As to BDNF levels, no differences concerning psychopathological profile, symptom 
severity and symptomatic improvement were found between the three subgroups. 
As compared to M-S100B, PANSS scores in H-S100B and L-S100B were significantly 
higher at baseline (p=0.003; data not shown). After 6 weeks of treatment, L-, M- and H-S100B 
subgroups showed a significant decrease on the various PANSS scores, except for the score on 
the PANSS negative subscale in H-S100B (p=0.347). Thus, negative symptoms did not improve 
in the subgroup with high baseline S100B levels. As can be seen in Figures 1 and 2, in the 
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L-S100B subgroup, the reduction in positive symptoms was less pronounced as compared to 
the H- and M-subgroups, reflected by a significantly higher mean PANSS positive score in 
the L-S100B subgroup after six weeks (between-group differences p=0.001). In contrast, as 
could be expected, mean PANSS negative score after six weeks was significantly higher in the 
H-S100B subgroup (between-group differences p=0.009).
Figure 1. PANSS Positive scores in S100B subgroups
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Legend to figure 1
PANSS positive scores at baseline and after 6 weeks of treatment of the low (n=14), middle (n=29) and high (n=15) 
subgroups, according to their baseline serum levels of S100B. Between-group differences: univariate analysis of variance, 
corrected for age and soft drugs, baseline p=0.003, 6 weeks p=0.001. *Within-group differences: paired t-test, all p≤0.001. 
 
Figure 2. PANSS Negative scores in S100B subgroups.
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Legend to figure 2
PANSS negative scores at baseline and after 6 weeks of treatment of the low (n=14), middle (n=29) and high (n=15) 
subgroups, according to their baseline serum levels of S100B. 
Between-group differences: univariate analysis of variance, corrected for age and soft drugs, baseline p=0.011, 6 weeks 
p=0.009. *Within-group differences: paired t-test, p≤0.006 in L- and M-S100B, H-S100B p=0.347.
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Discussion
In the present study serum levels of the neurotrophic proteins BDNF and S100B were measured 
in a group of patients with psychotic disorders before and after 6 weeks of treatment with 
antipsychotics. It was found that levels of BDNF are lowered in patients with an acute psychotic 
episode irrespective of diagnostic category, psychopathological profile or treatment effective-
ness. Furthermore, no effects were found for age or gender. 
Interestingly, reduction of positive symptoms was less pronounced in patients with a 
relatively low S100B level, whereas virtually no effect of treatment on negative symptoms was 
found in patients with a relatively high S100B level. The observation of lower serum levels of 
BDNF is in agreement with the findings by several other investigators15,17,20,21 and supports 
the hypothesis that psychotic disorders, of which schizophrenia is most widespread, may be 
considered as neurodevelopmental disorders indeed. Comparable observations have been 
made in patients with uni- and bipolar affective disorders.18,34,35 These observations indicate that 
BDNF may have pathophysiological implications across diagnostic boundaries. With respect 
to the effect of psychotropics on BDNF levels, equivocal results have been reported.15,22,36 
Nearly all literature mentions enhanced serum levels of S100B in schizophrenia.25,27,37 The 
present observation of subnormal S100B concentrations can therefore not easily be explained. 
This finding should be considered cautiously, especially since the difference between patients 
and controls was present at baseline only and the size of the study sample was modest. However, 
since S100B has neurotoxic as well as neurotrophic effects, it could be that this lower S100B 
level at baseline reflects deficiencies in neuroprotective mechanisms. 
Comparable considerations have to be taken into account for the observation that, in 
this study, more severe positive psychotic symptoms are associated with lower S100B levels. It 
could be speculated that subnormal levels of this neurotrophic protein might initially induce 
positive symptoms while during the course of disease S100B levels might rise, resulting in the 
development of negative symptoms due to a neurotoxic effect of the higher S100B levels in the 
brain.
The present observation that severity of negative psychotic symptoms is associated with 
higher S100B levels is in agreement with other reports26,28,29 and is suggestive for either a 
neurotoxic effect or a compensatory mechanism for damage already done. It should be stressed, 
however, that the H-S100B subgroup consisted of 15 patients only.
Although all potentially confounding factors have been included in the analyses14, 
interpretation of the here presented data still has to be done carefully since the study comprised 
a relatively small sample size with many differences between individual patients. The sample 
size, however, can be considered moderate when compared to other studies on BDNF or 
S100B, with study numbers varying between 18 and 88 patients with respect to BDNF16,19 and 
12 and 98 patients with respect to S100B.14,26 
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Given the diagnostic uncertainties in psychiatry in general38,39, instead of focusing 
on a particular category of psychoses (e.g. DSM-IV schizophrenia), the here chosen 
approach of including psychotic disorders irrespective of their classification may disclose 
a psychopathological phenotype that is associated with the functional status of one of the 
investigated neurotrophic proteins. This, in turn, may have consequences for either treatment 
or course of disease. It is therefore suggested that studies on pathophysiological determinants, 
e.g. neurotrophic proteins, of major psychiatric diseases like psychoses and affective disorders, 
should preferably follow a so-called dimensional approach searching for endophenotypes.40-42
In conclusion, this study, for the first time, demonstrates that patients with a relatively 
low serum level of S100B show less reduction in severity of positive psychotic symptoms 
after treatment with antipsychotics, whereas those with a relatively high S100B level hardly 
show any improvement of negative symptoms. Further studies are warranted to elucidate the 
pathophysiological significance and potential clinical implications of these observations. 
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Abstract
Background: Psychosis spectrum disorders, especially schizophrenia, have been linked to 
disturbed dopaminergic activity in the brain. Plasma homovanillic acid (pHVA) levels partly 
represent dopaminergic metabolism in the central nervous system. In the present study 
associations between (changes in) pHVA levels, symptom severity and symptomatic improve-
ment in patients with psychoses were investigated.
Methods: From a total of 80 patients, 58 fulfilled all inclusion criteria and their symptom 
profile and severity were assessed by means of the Comprehensive Assessment of Symptoms 
and History (CASH), the Positive and Negative Syndrome Scale (PANSS), and the Clinical 
Global Impression Scale for Severity and Improvement (CGI-S/CGI-I) at baseline and after 
six weeks of antipsychotic treatment. After inclusion, all patients were prescribed first- or 
second-generation antipsychotics by their treating psychiatrist. A total of twelve patients had 
first-episode psychosis (FEP). At both time points, pHVA levels were measured. Subsequently, 
pHVA levels were compared to an age-matched control sample and changes in pHVA levels 
(ΔpHVA) after treatment were associated with clinical parameters.
Results: Before analyses, data were scrutinized for possible confounders, partcicularly gender, 
smoking, medication status (including antipsychotic class) and recent drug use. The pHVA 
levels in patients were not different from those in controls. Treatment resulted in a significant 
decrease of all parameters. Symptomatic improvement as well as ΔpHVA was most pronounced 
in FEP patients.
Conclusion: These findings show that patients with FEP have a more favourable outcome 
than non-FEP-patients and that greater ΔpHVA also suggests that FEP patients still have the 
capacity to adjust dopaminergic neurotransmission.
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Introduction
Psychosis spectrum disorders, particularly schizophrenia, have been linked to dysregulated 
dopamine (DA) neurotransmission in the central nervous system. It has been demonstrated 
that DA hyperactivity in subcortical areas results in positive psychotic symptoms, whereas 
DA-hypoactivity in the frontal cortex is assumed to be involved in the evolution of negative 
symptoms.1 Although criticized by several investigators, the dopamine hypothesis is still the 
most comprehensive model for schizophrenia and related psychoses.2,3 
Homovanillic acid (HVA) is the main metabolite of DA, and 30-60% of plasma HVA 
(pHVA) is estimated to originate from DA neurons in the central nervous system. As a 
consequence, alterations in central DA activity are reflected by changes in plasma HVA levels 
(ΔpHVA).4 pHVA levels are widely used to study the function of central dopaminergic activity 
in psychiatric disorders and it has been shown that, following antipsychotic treatment, levels 
initially rise and later on return to normal or lowered values.5
As to pHVA in schizophrenia and related psychoses, both lowered and elevated levels 
have been reported, whereas some authors found no differences at all between patients and 
healthy controls.6,7 Low pHVA levels have been associated with deficit states8, whereas high 
baseline pHVA levels have been reported to be related with improvement of positive psychotic 
symptoms after treatment with antipsychotics.9 Elevated pHVA levels have been shown to 
be correlated with severity of psychotic symptoms during acute relapse10 and appeared to be 
present already in the prodromal phase of schizophrenia.11 Furthermore, some authors have 
reported differences in pHVA between patients with first episode psychosis (FEP) and those 
with relapsing or chronic psychoses, calling for further investigation.12
Associations have been established between baseline pHVA levels and overall improvement 
of psychotic symptoms or rapidity of response to antipsychotics in schizophrenia.13,14 In 
general, the results of studies about the effect of antipsychotic treatment on pHVA in patients 
with psychotic disorders are equivocal in that, depending on the antipsychotic agent, lowered 
(risperidone, olanzapine and aripiprazole)15,16, unchanged (clozapine)17, or elevated (haloperidol 
and olanzapine)18,19 levels have been reported. With respect to treatment response, comparable 
associations have been found in other psychosis spectrum disorders, such as schizoaffective 
disorder20, bipolar disorder21 and delusional disorder.22
Based on the hypothesis that pHVA reflects nature and severity of symptoms as well as 
treatment response, the present study was designed to investigate baseline pHVA and ΔpHVA 
in patients with both first episode and chronic relapsing psychosis spectrum disorders prior to 
and after 6 weeks of antipsychotic treatment.
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Methods
Patients
Patients were recruited from the Vincent van Gogh Institute for Psychiatry, a large teaching 
hospital in the south of the Netherlands, over a period of 2.5 years. Included were male 
and female patients (aged 18-65 years) hospitalized for psychotic symptoms necessitating 
psychopharmacological intervention and meeting the criteria for DSM-IV psychotic disorders. 
Intervention was defined as start or switch of antipsychotic agent or use of augmentation 
strategies. Excluded were patients with proven genetic syndromes, intellectual disability, or 
relevant somatic and neurologic disease as well as those who were unable to provide consent. 
All patients provided informed consent following Dutch medical ethical guidelines (CCMO 
registration number NL20469.097.07). The study was performed in accordance with the 
Declaration of Helsinki. 
Out of a total of 194 patients who were admitted during the study period, 100 met the 
inclusion criteria (71 were unable to provide informed consent, and in 23 the intended anti-
psychotic intervention was not implemented). Twenty patients refrained from participation 
for various reasons. Eventually, the study group comprised 80 patients of whom 58 completed 
the study period of 6 weeks. Relevant patient characteristics are summarized in Table 1.
Diagnostic procedures and treatment process
All assessments at baseline and after six weeks of treatment were performed by the same 
psychiatrist (first author). The Comprehensive Assessment of Symptoms and History 
(CASH)23 was applied at baseline as a diagnostic instrument and data were subsequently 
used for classification according to DSM-IV. To assess symptom profile and overall symptom 
severity, the Positive and Negative Syndrome Scale (PANSS)24 and Clinical Global Impression 
scale for severity and improvement (CGI-S/CGI-I)25 were used at both time points. All patients 
were prescribed first- or second-generation antipsychotic agents by the treating psychiatrist 
according to hospital standards. 
Response to antipsychotic treatment was defined as a reduction of at least 20% on the 
PANSS total score26 whereas for symptomatic remission the internationally accepted criteria 
were applied that comprise a selection of PANSS items with a cut-off score of ≤3 per item.27
Biochemical assessments
Patients: At both assessment dates, blood sampling to measure plasma HVA levels (nmol/l) 
was performed between 8 and 10 a.m. under fasting and resting conditions; plasma was stored 
at -80°C until analysis. All biochemical analyses were performed at the Neuropsychiatric 
Laboratory of the Erasmus Medical Centre (EMC). The technician was blinded to the clinical 
situation or diagnosis of the patients. HVA levels were measured by high performance liquid 
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chromatography using a Zorbax Eclipse XDB-C8 column (5 μm particle size, 250 x 3 mm; 
Agilent Technologies, Waldbronn, Germany) for separation. For the detection of HVA, we used 
an electrochemical detector (oxidation potential was set to 0.7 V) and the Intro controller (Antec 
Leyden, Leiden, The Netherlands). Quantification was done by measuring peak heights relative to 
two internal standards (isoprenaline and 5-methylserotonin). The mean recovery (± SD) of HVA 
added to the plasma samples was 95 ± 7%.
Table 1. Patient characteristics (n=58)
Gender (male/female)
Age (mean ±SD)
38/20 (66/34%)
36.7 ± 11.7 years
Age at first psychosis, years (mean ±SD)
Duration of psychotic illness, years (mean ±SD)
First episode psychosis yes/no
28.5 ± 11.1
8.1 ± 8.4
12/46 (21/79%)
Diagnosis (DSM-IV) Schizophrenia (n=33)
Schizoaffective disorder(n=2)
Brief psychotic disorder (n=8)
Bipolar disorder (n=7) *
Psychotic disorder NOS (n=6)
Delusional disorder (n=1)
Schizotypal personality disorder (n=1)
Smoking yes/no
Hard drugs in month prior to study entry yes/no
Soft drugs in month prior to study entry yes/no
38/20 (66/34%)
2/56 (3/97%)
10/48 (17/83%)
Medication status at study entry Naïve (n=10)
Free >2 weeks (n=8)
Using medication (n=40)
Medication used at study entry (n=40) 1 AP (n=15)
1 MS (n=5)
2 AP (n=6)
AP + AD (n=6)
AP+MS+AD (n=2)
AP+MS (n=4)
2 AP + AD (n=2)
Type of intervention (n=58) (Re)start AP (n=23)
Switch AP (n=26)
Augmentation of AP (n=2)
Switch + augmentation (n=1)
Significant dose increase (n=4)
Discontinuation of 1 AP (n=2)
Medication used after 6 weeks (n=58) 1 AP (n=35)
2 AP (n=4)
AP+AD (n=6)
AP+MS+AD (n=3)
AP+MS (9)
2 AP + AD (n=1)
Notes: values are n(%) or means ±SD. NOS= not otherwise specified; AP= antipsychotic agent (any), MS= mood stabilizer 
(any), AD= antidepressant (any)
* manic episode with psychotic features
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Controls: HVA levels of age-matched control subjects (n=75), sampled under similar 
conditions, were extracted from a large database of the Neuropsychiatric Laboratory of the 
EMC, consisting of staff members and students of the EMC and subjects from the general 
community, all without a personal or family history of psychiatric illness. Since no gender 
effects for HVA (p=0.98) were found in the control group and recent literature equally reports 
so28, control subjects were collected by age only.
Statistics
For statistical analyses, the 58 completers were included. In the case of normally distributed 
variables, parametric tests were applied, otherwise non-parametric tests were used. For 
nominal variables, Chi-square test was used. Mean comparisons were performed with Mann-
Whitney U (HVA levels) or Student’s t-test (PANSS scores), changes between time points 
with Wilcoxon signed-rank test (HVA) or paired t-test (PANSS scores) and correlations with 
Kendall’s Tau test. Between-group differences were calculated by means of a Kruskal-Wallis 
analysis of variance. Significance was set at p<0.05. All data are presented as mean ±SD, unless 
stated otherwise.
Results
Clinical data
Main characteristics of the patients, including diagnostic breakdown and medication status 
at relevant time points are presented in Table 1. As can be inferred, 18 out of 58 were free of 
medication at study entry, including 6 patients with relapsing psychosis. The remaining patients 
displayed psychotic symptoms despite treatment with various antipsychotic, mood stabilizing, 
or antidepressant agents. Of the total group, 19 patients, including all 12 FEP-patients, were 
admitted for the first time and 39 patients were re-admitted or permanently institutionalized.
As presented in Table 2, decreases in PANSS and CGI scores were all significant. 
Symptomatic reduction using the 20% response criterion was most pronounced on the PANSS 
positive subscale and illness severity decreased from marked to mild. As to FEP and non-FEP 
patients, at baseline, no differences were found with respect to severity of illness or remission 
status. After 6 weeks, both groups did not differ regarding their response while, as might be 
expected, significantly more patients in the FEP-group met the remission criterion.
Biochemical data
The pHVA levels in the patient group (n=58) at both time points (63.3 ± 25.9 and 55.0 ± 
19.1 nmol/l, respectively) were not significantly different from those in controls (53.4 ± 13.7 
nmol/l). The mean decrease in pHVA after six weeks (ΔpHVA) in the patient sample, however, 
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was significant (z = -2.45, p=0.014). In the total patient group, no correlations between ΔpHVA 
and changes in PANSS scores could be established.
Since several factors are known to influence DA activity in the brain, pHVA and ΔpHVA 
data were scrutinized for possible confounding effects of age, gender, smoking, recent drug 
use, medication status (naïve, free for at least two weeks, medicated), use of comedication 
(antidepressant, mood stabilizer or any), diagnosis (schizophrenic vs. non-schizophrenic 
psychosis), and antipsychotic class (first- vs. second-generation). At both time points, no 
associations were found between pHVA levels and any of these factors.
As to ΔpHVA, a significant higher change rate was found for FEP-patients (n=12) compared 
to those with (chronic) relapsing (n=46) psychoses (p=0.012). Data on the distribution of 
pHVA levels in FEP-patients are depicted in Figure 1.
Table 2. Clinical and biochemical parameters in total group, FEP patients, and non-FEP patients  
at baseline and after 6 weeks of treatment
Total group (n=58) FEP (n=12) Non-FEP (n=46)
PANSS baseline
- total
- positive
- negative
- global
84.9±19.4
22.7±6.3
19.8±7.2
42.3±9.5
73.9±12.3 c
21.8±4.3
15.3±4.6 c
36.8±7.9 c
87.8±20.0
22.9±6.8
21.0±7.2
43.8±9.5
PANSS 6 weeks
- total
- positive
- negative
- global
68.4±17.7 a
16.6±6.4 a
17.2±5.8 a
34.7±8.5 a
54.6±12.4 e
12.8±4.1 c
13.7±5.8 c
28.1±5.6 e
72.0±17.2
17.5±6.6
18.1±5.6
36.4±8.4
Mean CGI-Severity 
- baseline
- 6 weeks 
4.4±1.2
3.4±1.4 a
4.0±0.7
2.4±0.9 d
4.5±1.3
3.7±1.4
Number of patients
- response 
- remission baseline
- remission 6 weeks
30/58
8/58
21/58 
8/12
1/12
8/12 c
22/46
7/46
13/46
pHVA (nmol/l)
- baseline
- 6 weeks
ΔpHVA 
63.3±25.9
55.0±19.1 b
-8.2±23.7
69.5±29.4
48.7±13.1
-20.7±22.9 c
61.6±25.0
56.7±20.2
-4.9±23.1
Note.
a: difference treatment versus baseline, p<0.001
b: difference treatment versus baseline, p=0.014
c: difference between FEP and non-FEP group p<0.05
d: difference between FEP and non-FEP, p<0.01
e: difference between FEP and non-FEP, p≤0.001
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The difference between FEP and non-FEP patients was further analysed in terms of the 
aforementioned confounding factors. Only diagnosis and medication status were unevenly 
distributed (Χ2, p=0.020 and p=0.003, respectively), with diagnosis of schizophrenia being 
more dominant in the non-FEP group and antipsychotic medication less present in the FEP-
group. Concerning the latter, six patients were medication naïve and one had been treated 
previously with a non-antipsychotic agent. In addition, both subgroups were analysed on the 
relation between changes in pHVA and PANSS (subscale) scores. No significant correlations 
were found for any of the subgroups (FEP group: all p>0.273; non-FEP: all p>0.489).
Figure 1. Plasma HVA levels in FEP (n=12)
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Figur  1. Plasma HVA levels in FEP (n=12). 
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Legend to Figure 1 
Distribution of pHVA levels in FEP at baseline and after six weeks of treatment. Each dot 
represents an individual patient.  
 
Legend to Figure 1
Distribution of pHVA levels in FEP at baseline and after six weeks of treatment. Each dot represents an individual patient. 
Discussion
In the present study, pHVA levels were investigated in 58 patients with psychosis spectrum 
disorders before and after 6 weeks of treatment with antipsychotics. Overall, mean pHVA 
levels did not differ from a matched control sample, which is in line with the existing literature 
reporting inconclusive results.29
Baseline pHVA levels were not correlated with PANSS scores at both time points, 
indicating that this parameter has little prognostic value, as was already suggested in the 
nineties by other investigators.30 In contrast, data from the present study suggest that ΔpHVA 
may have a predictive value for responsiveness and possibly outcome in individual patients, as 
has also been suggested by others.31
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With respect to FEP-patients and patients with (chronic) relapsing psychoses, a significant 
difference in decrease of pHVA was found. Symptomatic improvement and reaching remission 
status was most pronounced in FEP-patients as repeatedly reported by other investigators.10,32 
These observations may be related to the individual’s state of neuroplasticity, as reflected by the 
ability to alter pHVA levels, especially since lack of plasticity is hypothesized to be related to 
loss of antipsychotic efficacy33,34, poor prognosis, and chronic course of disease.12,35
The observation of significant differences in ΔpHVA and remission status between FEP 
and non-FEP patients, irrespective of initial categorical diagnosis, stresses the importance of 
investigating psychoses across strict diagnostic boundaries of current classification systems. 
This idea is supported by the observation that, within the psychosis spectrum, multiple clinical 
phenotypes exist with different responses to treatment.7,9,36 The same holds for the association 
between ΔpHVA and antipsychotic responsivity in other psychosis spectrum disorders such as 
bipolar disorder21,37, schizoaffective disorder20 and delusional disorder.22
Several limitations can be identified that may have influenced the here reported results 
such as heterogeneity with respect to diagnostic classifications and antipsychotic treatment 
regimens. Concerning the latter, it is known that different antipsychotics may have a 
differential effect on pHVA levels15,38, albeit that in a recent study of Nishimura and coworkers, 
no association between pHVA and dose of antipsychotics could be established.39 
Nonetheless, in spite of the relatively small number of included patients, the observations 
on pHVA changes and responsiveness, remission status and outcome in FEP-patients can be 
considered rather robust.
In conclusion, the results from this study suggest that neuronal plasticity, expressed as 
ΔpHVA and reflecting the capacity to alter dopamine status, may be crucially involved in the 
individual responsiveness to antipsychotic treatment, especially in reaching the remission 
status.
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Abstract
Cycloid psychoses (CP) differ from schizophrenia regarding symptom profile, course, and 
prognosis and over many decades they are thought to be a separate entity within the psychosis 
spectrum. As to schizophrenia, research into the pathophysiology has focused at dopamine, 
Brain-derived Neurotrophic Factor (BDNF), and glutamate signaling in which, concerning 
the latter, the N-methyl-D-aspartate receptor plays a crucial role. The present study aims to 
determine whether CP can biochemically be delineated from schizophrenia. 
Eighty patients referred for psychotic disorders were assessed with the Comprehensive 
Assessment of Symptoms and History, and (both at inclusion and after 6 weeks of antipsychotic 
treatment) with the Positive and Negative Syndrome Scale and Clinical Global Impression. 
From 58 completers, 33 patients were diagnosed with schizophrenia and 10 with CP psychoses 
according to DSM-IV and Leonhard criteria, respectively. Fifteen patients were diagnosed 
with other disorders within the psychosis spectrum. At both time points, blood levels of 
the dopamine metabolite homovanillic acid, BDNF, and amino acids related to glutamate 
neurotransmission were measured and compared with a matched control sample. 
Patients with CP showed a significantly better response to antipsychotic treatment as compared 
to patients with schizophrenia. In CP, glycine levels were elevated and tryptophan levels were 
lowered as compared to schizophrenia. Glutamate levels were increased in both patient groups 
as compared to controls.
These results, showing marked differences in both treatment outcome and glutamate-related 
variable parameters, may point at better neuroplasticity in CP, necessitating demarcation of 
this subgroup within the psychosis spectrum.
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Introduction
Over many decades, dopamine (DA) neurotransmission has been thought to be the main 
mechanism in the pathophysiology of psychotic disorders, and DA-receptor antagonists 
have been demonstrated to be effective in reducing -mainly positive- psychotic symptoms.1 
Subsequent research has disclosed that other neurotransmitter systems, particularly that 
of glutamate, are associated with negative symptoms and cognitive dysfunctions via the 
N-methyl-D-aspartate (NMDA) receptor 2-5
Glutamate is the most abundant excitatory neurotransmitter in the human brain and 
glutamatergic receptors are involved in regulating neuronal migration, growth and pruning 
(i.e. neuroplasticity).6,7 Glutamate acts at different types of receptors, of which the NMDA 
receptor is the most investigated.8,9 Glycine acts as a co-agonist at the NMDA receptor and can 
potentiate glutamatergic neurotransmission.10 In contrast, antagonizing the NMDA receptor 
by means of phencyclidine (PCP) or ketamine induces schizophrenia-like symptoms.11,12
These observations have led to the hypothesis that the pathophysiology of schizophrenia 
is at least partly related to impairment in NMDA neurotransmission.13,14 Hence, it seems 
likely that enhancing NMDA activity might benefit patients with schizophrenia, which could 
possibly be achieved by administration of components targeting at the glutamate system.8,10,15,16
Cycloid psychoses (CP) as described by Leonhard in the 1950s, partly operationalized by 
Perris and Brockington and included in ICD-10 as acute polymorphic psychotic disorder, differs 
from schizophrenia with respect to symptom profile, course and prognosis.17-20 According to 
Leonhard, three subtypes can be delineated: anxiety-happiness psychosis, confusion psychosis 
and motility psychosis, all showing a pleiomorphic symptom profile with intraphasic bipolarity. 
In general, full recovery is reached without residual negative symptoms or cognitive decline.21-23 
CP, as such, are not included in DSM-IV, although key symptoms like pananxiety, perplexity 
and motility disorders have been demonstrated in a substantial percentage of patients.24-30 An 
overview of the characteristics of schizophrenia and CP is presented in Table 1.
Since CP differ significantly from schizophrenia, the hypothesis was formulated that 
they could also be distinct on their biochemical profile, especially regarding glutamatergic 
transmission. Therefore, in the present study, peripheral levels of amino acids related to 
glutamate signaling (i.e. glutamate, glycine, and tryptophan) were measured in a group of 
patients with psychosis spectrum disorders. In addition, levels of Brain-derived Neurotrophic 
Factor (BDNF) and the dopamine metabolite homovanillic acid (HVA) were determined, 
reflecting neuroplasticity and dopaminergic activity, respectively.
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Table 1. Characteristic differences between schizophrenia and cycloid psychoses
Schizophrenia Cycloid psychoses
Onset Slow and insidious (weeks to months) Often acute (hours to days)
Age at onset Adolescence / young adulthood Any age
Symptomatology Delusions, hallucinations, 
disorganization, negative symptoms
Perplexity, confusion, mood swings, 
motility disorders, hallucinations, 
ideas of self sacrifice
Course Relapsing and remitting, chronic, 
gradual functional and cognitive 
decline
Full remission, relapsing course 
without negative or cognitive decline
Prognosis Unfavourable Favourable
Treatment Antipsychotic agents Low potent antipsychotic agents in 
acute phase, limited evidence for 
maintenance treatment (lithium 
carbonate)
Gender 
distribution
Male ≈ female Male < female
Methods
Patients
Patients were recruited over a 2.5 year period at the Vincent van Gogh Institute for Psychiatry. 
Included were adult male and female patients meeting DSM-IV criteria for psychosis spectrum 
disorders, who required antipsychotic treatment intervention. Intervention was defined as 
start or switch of antipsychotic agent or use of augmentation strategies. Exclusion criteria 
were known genetic syndromes or intellectual disability, and somatic or neurologic disorders 
interfering with treatment as usual. Research was performed in accordance with the Declaration 
of Helsinki and was approved by the regional ethics committee (METiGG) and board of 
directors of Vincent van Gogh Institute. Written informed consent was obtained following 
Dutch ethical guidelines (CCMO registration number NL20469.097.07). After inclusion, all 
patients were prescribed first- or second-generation antipsychotic agents (FGA/SGA) by their 
treating psychiatrist following standard professional guidelines. Concomitant treatment with 
two antipsychotic agents, mood stabilizer and/or antidepressant was allowed and documented.
During the study period, 194 patients were identified as eligible for inclusion. However, from 
these 194 patients, 71 were considered unable to provide informed consent because of severity 
of illness. In another 23 patients the intended pharmacological intervention was not performed, 
yielding 100 patients who were eligible for inclusion. Twenty patients refused to participate, 
mostly because of the need for venipuncture, resulting in a study group of 80 patients. Of them, 
58 completed all clinical and biochemical assessments at baseline and after 6 weeks.
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Diagnostic procedures
All patients were assessed by the first author (NvdK) before or within one week after start of 
treatment with antipsychotics. At baseline, the Comprehensive Assessment of Symptoms and 
History (CASH) was applied to establish diagnoses according to DSM-IV.31 The Positive and 
Negative Syndrome Scale (PANSS) and Clinical Global Impression of Severity and Improvement 
(CGI-S/I) were used to measure symptom profile and overall disease severity at baseline and 
after 6 weeks.32,33 PANSS cognitive score was calculated according to the procedure as described 
by Lindenmayer et al.34 To establish diagnoses of CP, a symptom checklist according to Leonhard 
was completed by NvdK and a clinician trained in establishing diagnoses according to Leonhard 
(MS).26,30,35 Final diagnoses were made in a so-called LEAD conference, in which all possible and 
probable cases of CP were discussed with two experts in the field of CP (GS and WV).36
Biochemical analyses
Patients: Blood samples were collected by means of venipuncture between 8 and 10 a.m. at both 
assessment dates to determine BDNF, HVA, the amino acids glutamate, glycine and tryptophan, and 
the ratio between tryptophan and the 5 large neutral amino acids (LNAA) competing for the same 
transport system, being leucine, isoleucine, valine, phenylalanine and tyrosine (Trp/LNAA ratio).
Plasma was prepared after centrifugation of EDTA blood for 20 min at 2650 g and 
20°C, and stored at -80°C until analysis. All biochemical analyses were performed at the 
Neuropsychiatric Laboratory of Erasmus University Medical Center (EMC), Rotterdam, and 
the technician was blinded to the clinical situation and diagnosis of the patients. 
Plasma was deproteinized and amino acids were separated by high performance liquid 
chromatography and detected by fluorescence after derivatization with ortho-phthaldialdehyde 
as described previously.37 HVA levels were measured after deproteinization of plasma by 
high performance liquid chromatography using a Zorbax Eclipse XDB-C8 column (5 μm 
particle size, 250 x 3 mm; Agilent Technologies, Santa Clara, CA, USA) for separation. For 
the detection of HVA, an electrochemical detector (oxidation potential was set to 0.7 V) and 
the Intro controller (Antec Leyden, Zoeterwoude, The Netherlands) were used. Quantification 
was done by measuring peak heights relative to two internal standards (isoprenaline and 
5-methylserotonin). The mean recovery (± SD) of HVA added to the plasma samples was 
95 ± 7%. BDNF was measured in serum by a double antibody sandwich enzyme linked 
immunosorbent assay (ELISA) (Promega Corporation, Madison, WI, USA).
Controls: Biochemical parameters from age-matched controls were taken from a large 
database of the aforementioned Neuropsychiatric Laboratory. Age-matched controls were 
taken from a large database, consisting of hospital staff and students and subjects from the 
general community, all without a personal or family history of psychiatric illness. Mean age of 
the control group (n=75) was 37.9 ± 10.1 years.
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Statistics
From the 58 completers, only patients with a diagnosis of schizophrenia (n=33) or CP (n=10) 
were included in the statistical analyses. To compare means, the non-parametric Mann-Whitney 
U test was used for non-normally distributed data (biochemical parameters) whereas the 
Student’s t-test was applied for normally distributed data. To investigate changes between time 
points, Wilcoxon Signed rank test (biochemical parameters) or paired t-test (PANSS scores) 
was used. For binary variables, a Chi-square test was done. Significance was set at p<0.05. All 
data are presented as mean ± SD, unless stated otherwise.
Results
Patients:
By excluding patients diagnosed with other psychotic disorders (n=15), the study sample 
(n=43) consisted of 30 males and 13 females with a mean age of 34.8 ± 11.3 years. Thirty-
three patients received a diagnosis of schizophrenia and in ten, a diagnosis of CP according 
to Leonhard was made (anxiety-happiness: n=5; confusion: n=2; motility: n=3). Mean age at 
first psychosis was 26.5 ± 9.8 years and mean duration of psychotic illness was 8.3 ± 8.1 years. 
Fourteen patients (CP: n=5; schizophrenia: n=9) did not receive psychotropic medication 
prior to inclusion in the study (referred to as “at baseline”), of which 8 were antipsychotic naïve 
(CP: n=3; schizophrenia: n=5). Eight out of the total of 43 patients were first-episode psychosis 
(FEP) patients. Five patients were classified as both medication naïve and having FEP (CP: 
n=3; schizophrenia: n=5). Details on symptom clusters, effect of antipsychotic treatment and 
severity of illness are summarized in Table 2.
Since each patient received an individually targeted treatment, data were scrutinized for 
possible confounding effects of psychopharmacological heterogeneity. With respect to the two 
patient groups (CP: n=10; schizophrenia: n=33), no differences were found as to medication 
status (naïve, free >2 weeks, or medicated), use of co-medication (antidepressant or mood 
stabilizers), and antipsychotic class (FGA or SGA). Regarding the latter, in the CP group, none 
of the patients was treated with clozapine, whereas nine patients in the schizophrenia group 
did receive this agent. The CP group comprised significantly more females, who had higher 
ages at first presentation of psychotic illness as well as at time of inclusion. Finally, five patients 
with CP were defined as FEP patients. 
As can be inferred from Table 2, CP patients had significantly lower scores on the PANSS 
total, positive and negative scale at both time points. Symptomatic improvement was most 
marked in the positive symptom cluster. While both groups showed symptomatic improvement 
after 6 weeks of treatment, a significant difference was found between the groups in PANSS 
cognitive score and CGI-S in favour of the CP group.
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Table 2. Demographic and clinical parameters in patients with cycloid psychosis (CP, n=10)  
and schizophrenia (n=33)
CP (n=10) Schizophrenia (n=33)
Male/female *
Age *
Age at onset *
FEP yes/no **
4/6
42.3 ± 10.3
36.7 ± 10.8
5/5
26/7
32.6 ± 10.8
23.4 ± 7.1
3/30
Smoking yes/no1 *
Caffeine yes/no1
Softdrugs yes/no1
Harddrugs yes/no1
3/7
9/1
1/9
0/10
25/8
29/4
7/26
2/31
PANSS baseline
- Total score *
- Positive subscale *
- Negative subscale **
- Global subscale
- Cognitive subscale
77.2 ± 19.1
20.2 ± 5.8
16.6 ± 5.8
40.4 ± 11.7
13.1 ± 4.4
92.9 ± 17.4
25.0 ± 5.5
22.9 ± 6.8
45.1 ± 9.1
15.3 ± 3.9
PANSS 6 weeks
- Total score *
- Positive subscale **
- Negative subscale *
- Global subscale
- Cognitive subscale *
55.4 ± 22.2
11.5 ± 6.5
13.8 ± 6.1
30.1 ± 11.7
9.8 ± 4.5
75.3 ± 13.3
18.9 ± 5.2
19.4 ± 5.1
37.0 ± 6.9
13.1 ± 3.4
Mean CGI Severity (CGI-S)
- baseline 
- 6 weeks *
Mean CGI Improvement (CGI-I)
4.0 ± 1.2
2.5 ± 1.4
2.4 ± 1.0
4.9 ± 1.1
4.0 ± 1.1
2.9 ± 0.9
Abbreviations: FEP = first episode psychosis; PANSS = Positive and Negative Syndrome Scale; CGI = Clinical Global Impression
1 Smoking and use of caffeine/ softdrugs/ harddrugs were defined as any use ≠ 0 in the past month, as reported by the patient.
All within-group differences between PANSS and CGI scores at baseline and after six weeks are significant (p≤0.001) 
except for PANSS negative score in the CP group (p=0.062)
* difference between CP and schizophrenia, Mann Whitney U, p<0.05
**difference between CP and schizophrenia, Mann Whitney U, p≤0.01
 
Biochemical parameters:
As compared to controls, serum BDNF levels were lowered in patients with schizophrenia, and 
plasma glutamate levels appeared to be increased in both patient groups. Concerning plasma 
levels of glycine, significant higher values were found in CP patients at both time points as 
compared to patients with schizophrenia as well as control subjects. Also, at both time points, 
plasma tryptophan levels were significantly lower in patients with CP as compared to controls, 
but differed only at baseline from the schizophrenia group. Trp/LNAA ratio was lowered in 
both patient groups as compared to controls. Plasma levels of HVA did not differ between the 
groups. All data are presented in Table 3.
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Table 3. Blood levels of biochemical parameters in cycloid psychosis (CP, n=10), schizophrenia  
(SCH, n=33) and controls (n=75)
CP Schizophrenia Controls
BDNF baseline1 
BDNF 6 weeks1
20.4 ± 7.1
19.9 ± 8.1
19.6 ± 5.8***
19.1 ± 6.0***
24.4 ± 6.7
HVA baseline2 
HVA 6 weeks2
60.4 ± 21.3
51.8 ± 20.4
58.5 ± 19.7
52.1 ± 15.8
53.4 ± 13.7
Glutamate baseline3
Glutamate 6 weeks3
56.3 ± 24.8**
64.9 ± 44.6**
69.5 ± 30.5***
66.2 ± 30.9***
34.4 ± 16.1
Glycine baseline3
Glycine 6 weeks3
292.2 ± 96.9*
280.9 ± 86.2*
215.1 ± 62.3#
223.7 ± 62.3#
224.2 ± 47.8
Tryptophan baseline3
Tryptophan 6 weeks3
37.4 ± 14.0**
38.1 ± 10.8**
48.3 ± 11.5#
43.5 ± 11.7
47.5 ± 7.7
Trp/LNAA ratio baseline
Trp/LNAA ratio 6 weeks
7.1 ± 1.4**
7.4 ± 1.6*
7.7 ± 1.5*
7.8 ± 1.7*
8.6 ± 1.5
Phenylalanine baseline3
Phenylalanine 6 weeks3
52.4 ± 10.2
51.7 ± 10.1
63.4 ± 15.1*#
55.3 ± 11.2
56.3 ± 8.9
Isoleucine baseline3
Isoleucine 6 weeks3
69.1 ± 22.1
63.6 ± 19.6
82.7 ± 32.8
71.8 ± 22.1
71.0 ± 22.2
Leucine baseline3
Leucine 6 weeks3
121.7 ± 36.0
123.3 ± 39.5
158.5 ± 60.0*
136.9 ± 39.2
130.3 ± 32.4
Valine baseline3
Valine 6 weeks3
218.7 ± 65.2
218.7 ± 49.8
267.6 ± 76.1
239.6 ± 58.0
245.3 ± 56.6
Tyrosine baseline3
Tyrosine 6 weeks3
61.5 ± 14.9
61.5 ± 18.7
72.2 ± 25.6
62.1 ± 15.4
63.9 ± 17.0
1 = µg/l; 2 = nmol/l; 3 = µmol/l
Abbreviations: BDNF = brain derived neurotrophic factor; HVA = homovanillic acid; Trp/LNAA ratio = tryptophan/large 
neutral amino acids ratio
Difference versus controls (Mann-Whitney U)
* p<0.05; ** p≤0.01; *** p≤0.001
# difference between SCH and CP, p<0.05
In both the subgroup of patients with schizophrenia who were treated with clozapine 
(n=9) and the subgroup of eight medication naïve patients (CP: n=3; schizophrenia: n=5), 
lowered serum levels of BDNF and elevated levels of glutamate were found at both time points. 
However, in the clozapine subgroup, glycine levels were significantly lowered as compared to 
controls at baseline (177.6 ± 45.1 versus 224.2 ± 47.8 µmol/l), whereas in the medication-naïve 
subgroup glycine levels did not differ from controls at both time points.
The fifteen patients with diagnoses other than CP or schizophrenia (schizoaffective 
disorder: n=1; bipolar disorder: n=5; delusional disorder: n=1; brief psychotic disorder: n=2; 
schizotypal personality disorder: n=1, psychotic disorder not otherwise specified: n=5) were 
analyzed separately. Glutamate levels were significantly elevated as compared to controls at 
both time points. Data on biochemical parameters in this group are depicted in Table 4.
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Table 4. Blood levels of biochemical parameters in patients with other psychotic disorders (n=15) 
and controls (n=75)
Baseline 6 weeks Controls
BDNF1 21.9 ± 8.1 20.4 ± 7.6 24.4 ± 6.7
HVA2 75.5 ± 36.6 63.5 ± 23.3 53.4 ± 13.7
Glutamate3 51.1 ± 13.9 *** 50.9 ± 16.6 *** 34.4 ± 16.1
Glycine3 268.5 ± 137.5 263.7 ± 124.9 224.2 ± 47.8
Tryptophan3 47.4 ± 9.6 46.0 ± 7.8 47.5 ± 7.7
Trp/LNAA ratio 7.9 ± 2.2 8.0 ± 1.6 8.6 ± 1.5
Phenylalanine3 59.8 ± 12.0 58.3 ± 10.4 56.3 ± 8.9
Isoleucine3 81.1 ± 23.1 72.7 ± 22.3 71.0 ± 22.2
Leucine3 149.4 ± 43.2 141.6 ± 38.7 130.3 ± 32.4
Valine3 264.4 ± 52.4 252.1 ± 65.1 245.3 ± 56.6
Tyrosine3 73.7 ± 21.1 70.5 ± 20.7 63.9 ± 17.0
1 = µg/l; 2 = nmol/l; 3 = µmol/l
Abbreviations: BDNF = brain derived neurotrophic factor; HVA = homovanillic acid; Trp/LNAA ratio = tryptophan/large 
neutral amino acids ratio
Difference versus controls (Mann-Whitney U)
* p<0.05; ** p≤0.01; *** p≤0.001
As to intercorrelations of biochemical and clinical parameters, both in the total patient 
sample and in the schizophrenia subgroup, baseline glutamate levels were positively correlated 
with changes in PANSS cognitive scores (total sample: T 0.280, p=0.012; schizophrenia: 
T 0.360, p=0.005). Glutamate levels after six weeks were positively correlated with PANSS 
cognitive scores at both time points in the total patient group (baseline T 0.221, p=0.043; six 
weeks T 0.279, p=0.011) and with PANSS cognitive scores after six weeks in schizophrenia 
patients (T 0.289, p=0.023). 
Baseline glycine levels did not correlate with any of the clinical (sub)scales. Glycine levels 
after six weeks correlated significantly with changes in PANSS cognitive scores (T 0.523, 
p=0.038) in CP patients. No other correlations were found in CP between glutamate or glycine 
levels and other PANSS or CGI scores at both time points. 
No significant correlations were found for (changes in) any of the biochemical parameters 
from Table 3 and (changes in) other clinical parameters (PANSS or CGI) in the two subgroups 
at both time points. 
Discussion
In this study, patients with CP and schizophrenia were assessed on both clinical and biochemical 
profiles. Essentially, the CP group showed better clinical outcome than the schizophrenia 
group and differed significantly in terms of biochemical parameters, particularly plasma levels 
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of glycine and tryptophan. Serum levels of BDNF were significantly lower in the schizophrenia 
group as compared to controls. 
With respect to glycine, in CP, plasma levels were elevated as compared to both schizo-
phrenia and healthy controls. Although in 2004, Sumiyoshi and coworkers found lowered levels 
of glycine for schizophrenia in comparison with controls and patients with major depression, 
current findings are in line with those reported in 2006 by Hoekstra et al. in patients with 
bipolar mania.38,39
Since glycine is an essential co-agonist for glutamate at the NMDA receptor, increased 
levels could be regarded as a reflection of disturbances in glutamatergic neurotransmission. 
With respect to the latter, since plasma glutamate levels did not differ significantly between 
the two groups, it could be speculated that in CP, glycine levels are elevated as a compensatory 
reaction to NMDA receptor hypofunction, whereas patients with schizophrenia would have 
insufficient neuroplasticity to produce such a response. This hypothesis is corroborated by the 
present lowered serum BDNF levels in the schizophrenia group and by other studies showing 
that PCP-induced psychotic symptoms can be ameliorated by administration of glycine.40,41 
Further support is found in earlier studies that show beneficial effects of adjuvant high-dose 
glycine augmentation to other antipsychotic agents.42-44 
In patients with other psychotic disorders, both BDNF and glycine levels did not differ 
from controls. It could be speculated that, even in the presence of sufficient neuroplasticity, the 
ability to adaptively increase glycine levels might be characteristic for CP.
The observation that plasma levels of glutamate are increased in all patient groups 
as compared to controls, is in accordance with reports that relate elevated glutamate levels 
with psychosis and psychotic relapse, albeit that decreased levels in schizophrenia and 
bipolar disorders have also been reported.29,45,46 Elevated glutamate levels are hypothesized 
to be the result of NMDA receptor hypofunction, leading to diminished glutamatergic 
neurotransmission and to the evolvement of schizophrenic symptoms, including negative and 
cognitive symptoms.15,16 
The Trp/LNAA ratio was significantly lower in CP and schizophrenia as compared 
to controls. This finding is suggestive of a decreased central serotonergic activity in both 
patient groups. The lower tryptophan levels in CP might point to an increased breakdown of 
tryptophan via the kynurenine pathway. One of the products in this pathway is kynurenic acid, 
which is not only an antagonist of the NMDA receptor, but also a neuroprotectant.47,48 It could 
be speculated that in CP, other than in schizophrenia, this neuroprotective mechanism is still 
activated which would correspond with better neuroplastic properties and a more favourable 
course of disease in CP.
Apart from small sample size and the use of peripheral measurements only, a limitation 
can be identified in that a substantial number of patients were treated earlier with a wide range 
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of FGA and SGA agents. The latter, however, most probably did not interfere with the results 
since no influences were found regarding medication status in the two patient groups.
In conclusion, in both CP and schizophrenia, systemic glutamate metabolism and the Trp/
LNAA ratio were altered, which could be related to changes in glutamate signaling. Moreover, 
differences in especially glycine, between CP and schizophrenia were found, which may point 
at a better neuroplasticity in CP than in schizophrenia. This may be in line with better clinical 
outcome in CP. Therefore, it is crucial to identify CP as a separate group of disorders within 
the psychosis spectrum.
Acknowledgement 
The authors would like to thank M.K.F. Schneider, MD, PhD, for the critical evaluation of 
diagnoses in all patients and to A.E.S. Sijben, MSc, PhD, for assistance with statistical analyses. 
The authors are indebted to Mrs A. Voskuilen-Kooijman from the Neuropsychiatric Laboratory 
of the Department of Clinical Chemistry of the Erasmus Medical Centre for biochemical 
analyses.
84
References
1. Kapur S, Mizrahi R, Li M. From dopamine 
to salience to psychosis – linking biology, 
pharmacology and phenomenology of 
psychosis. Schizophr Res. 2005;79:59-68.
2. Javitt DC, Liederman E, Cienfuegos A, Shelley 
AM. Panmodal processing imprecision as a 
basis for dysfunction of transient memory 
storage systems in schizophrenia. Schizophr 
Bull. 1999; 25:763-775.
3. Stone JM, Morrison PD, Pilowsky LS. 
Glutamate and dopamine dysregulation in 
schizophrenia - a synthesis and selective review. 
J Psychopharmacol. 2007;21:440-452.
4. Möhler H, Rudolph U, Boison D, Singer P, 
Feldon J, Yee BK. Regulation of cognition and 
symptoms of psychosis: Focus on GABAA 
receptors and glycine transporter 1’. Pharmacol 
Biochem Behav. 2008;90:58-64.
5. Gruber O, Chadha Santuccione A, Aach H. 
Magnetic resonance imaging in studying 
schizophrenia, negative symptoms, and the 
glutamate system. Front Psychiatry. 2014;5:32.
6. Luján R, Shigemoto R, López-Bendito G. 
Glutamate and GABA receptor signaling in the 
developing brain. Neuroscience. 2005;130:567-
580.
7. Manent JB, Represa A. Neurotransmitters 
and brain maturation: early paracrine actions 
of GABA and glutamate modulate neuronal 
migration. Neuroscientist. 2007;13: 268-279.
8. Stone JM. Glutamatergic antipsychotic drugs: 
a new dawn in the treatment of schizophrenia? 
Ther Adv Psychopharmacol. 2011;1:5-18.
9. Veerman SRT, Schulte PFJ, De Haan L. The 
glutamate hypothesis: a pathogenic pathway 
from which pharmacological interventions have 
emerged. Pharmacopsychiatry. 2014;47:121-130.
10. De Bartolomeis A, Sarappa C, Magara S, Iasevoli 
F. Targeting the glutamate system for novel 
antipsychotic approaches: relevance for residual 
psychotic symptoms and treatment resistant 
schizophrenia. Eur J Pharmacol. 2012;682:1-11.
11. Javitt DC, Zukin SR. Recent advances in the 
phencyclidine model of schizophrenia. Am J 
Psychiatry. 1991;148:1301-1308.
12. Dandash O, Harrison BJ, Adapa R, et al. 
Selective augmentation of striatal functional 
connectivity following NMDA receptor 
antagonism: implications for psychosis. 
Neuropsychopharmacology. 2015;40(3):622-631.
13. Gordon JA. Testing the glutamate hypothesis of 
schizophrenia. Nat Neurosci. 2010;13:2-4.
14. Javitt DC. Twenty-five years of glutamate in 
schizophrenia: are we there yet? Schizophr Bull. 
2012;38:911-913.
15. Schmitt A, Hasan A, Gruber O, Falkai P. 
Schizophrenia as a disorder of disconnectivity. 
Eur Arch Psychiatry Clin Neurosci. 
2011;261:S150-154.
16. Zink M, Englisch S, Schmitt A. Antipsychotic 
treatment modulates glutamate transport and 
NMDA receptor expression. Eur Arch Psychiatry 
Clin Neurosci. 2014;264:S67-S82.
17. World Health Organization. The ICD-10 classi-
fication of mental and behavioural disorders. 
Clinical descriptions and diagnostic guidelines. 
Geneva, World Health Organization, 1992. 
18. Leonhard K. Aufteilung der endogenen 
Psychosen. Berlin, Akademie, 1957.
19. Perris C, Brockington IF. Cycloid psychoses 
and their relation to the major psychoses. In: 
Perris C, Struwe D, Jansson B (Eds). Biological 
Psychiatry. Amsterdam, Elsevier, 1981:447-450.
20. Jabs BE, Pfuhlmann B, Bartsch AJ, Cetkovich-
Bakmas MG, Stöber G. Cycloid psychoses – 
from clinical concepts to biological foundations. 
J Neural Transm. 2002;109: 907-919.
21. Beckmann H, Franzek E. Cycloid psychoses 
and their differentiation from affective and 
schizophrenic psychoses. In: F. Henn , N. 
Sartorius, H. Helmchen, H. Lauter H (Eds.). 
Contemporary Psychiatry volume 3. Heidelberg, 
Springer Verlag, 2001:387-398.
22. Jabs BE, Krause U, Althaus G, Bartsch AJ, 
Stöber G, Pfuhlmann B. Differences in quality 
of life and course of illness between cycloid and 
schizophrenic psychoses – a comparative study. 
World J Biol Psychiatry. 2004;5:136-142.
23. Salvatore P, Bhuvaneswar C, Ebert D, Maggini 
C, Baldessarini, RJ. Cycloid psychoses revisited: 
case reports, literature review, and commentary. 
Harv Rev Psychiatry. 2008;16:167-180. 
24. 24.American Psychiatric Association. Diagnostic 
and statistic manual of mental disorders (4th ed). 
Washington, American Psychiatric Association, 
1994.
25. Lindvall M, Axelsson R, Öhman, R. Incidence 
of cycloid psychosis: A clinical study of 
first-admission psychotic patients. Eur Arch 
Psychiatry Clin Neurosci. 1993;242: 197-202. 
85
B
iochem
istry in cycloid psychoses
6
26. Pfuhlmann B. Das Konzept der zykloiden 
Psychosen. Fortschr Neurol Psychiat. 1998;66: 
1-9.
27. Peralta V, Cuesta MJ. Cycloid psychosis : a 
clinical and nosological study. Psychol Med. 
2003;33:443-453.
28. Peralta V, Cuesta MJ. Cycloid psychosis. Int Rev 
Psychiatry. 2005;17:53-62.
29. Van der Heijden FM, Tuinier S, Fekkes D, Sijben 
AES, Kahn RS, Verhoeven WMA. Atypical 
antipsychotics and the relevance of glutamate 
and serotonin. Eur Neuropsychopharmacol. 
2004;14:259-265.
30. Van de Kerkhof NW, Van der Heijden FM, 
Schneider MK, et al. Cycloid psychoses: 
Leonhard’s descriptions revisited. Eur J Psychiat. 
2012;26:266-278.
31. Andreasen NC, Flaum MC, Arndt S. The 
comprehensive assessment of symptoms and 
history (CASH): an instrument for assessing 
diagnosis and psychopathology. Arch Gen 
Psychiatry. 1992;49:615-623.
32. Kay SR, Fiszbein A, Opfer L. The positive 
and negative syndrome scale (PANSS) for 
schizophrenia. Schizophr Bull. 1987;13:261-176.
33. Guy W. ECDEU Assessment manual for 
psychopharmacology, revised. Bethesda, National 
Institute of Mental Health, 1976. 
34. Lindenmayer JP, Bernstein-Hyman R, 
Grochowski S. Five-factor model of 
schizophrenia: initial validation. J Nerv Ment 
Dis. 1994;182:631-638.
35. Leonhard K. Differenzierte Diagnostik 
der endogenen Psychosen, abnormen 
Persönlichkeitsstrukturen und neurotischen 
Entwicklungen. Berlin, Verlag Gesundheit 
GmbH, 1963.
36. Skodol AE, Rosnick L, Kellmann D, Oldham 
JM, Hyler S. Development of a procedure for 
validating structured assessment of axis II. In 
JM Oldham (Ed.) Personality disorders: new 
perspectives on diagnostic validity. Washington, 
American Psychiatric Press, 1991:43-70.
37. Fekkes D, Van Dalen A, Edelman M, Voskuilen 
A. Validation of the determination of amino 
acids in plasma by high-performance liquid 
chromatography using automated pre-column 
derivatization with o-phthaldialdehyde. J 
Chromatogr B Biomed Appl. 1995;669(2):177-
186.
38. Sumiyoshi T, Anil AE, Jin D, Jayathilake K, Lee 
M, Meltzer HY. Plasma glycine and serine levels 
in schizophrenia compared to normal controls 
and major depression: relation to negative 
symptoms. Int J Neuropsychopharmacol. 
2004;7:1-8.
39. Hoekstra R, Fekkes D, Loonen AJM, 
Pepplinkhuizen L, Tuinier S, Verhoeven 
WMA. Bipolar mania and plasma amino 
acids: increased levels of glycine. Eur 
Neuropsychopharmacol. 2006;16:71-77.
40. D’Souza DC, Singh N, Elander J, et al. 
Glycine transporter inhibitor attenuates 
the psychomimetic effects of ketamine 
in healthy males: preliminary evidence. 
Neuropsychopharmacology 2012;37:1036-1046.
41. Woods SW, Walsh BC, Hawkins KA, et al. 
Glycine treatment of the risk syndrome for 
psychosis: report of two pilot studies. Eur 
Neuropsychopharmacol 2013;23: 931-940.
42. Heresco-Levy U, Javitt DC, Ermilov M, Mordel 
C, Horowitz A, Kelly D. Double-blind, placebo-
controlled, crossover trial of glycine adjuvant 
therapy for treatment-resistant schizophrenia. 
Br J Psychiatry. 1996;169:610-617.
43. Heresco-Levy U, Javitt DC, Ermilov M, Mordel 
C, Silipo G, Lichtenstein M. Efficacy of high-
dose glycine in the treatment of enduring 
negative symptoms of schizophrenia. Arch Gen 
Psychiatry. 1999;56:29-36.
44. Heresco-Levy U, Ermilov M, Lichtenberg P, 
Bar G, Javitt DC. High-dose glycine added to 
olanzapine and risperidone for the treatment of 
schizophrenia. Biol Psychiatry 2004;55:165-171.
45. Ivanova SA, Boyko AS, Fedorenko OY, 
Krotenko NM, Semke AV, Bokhan NA. 
Glutamate concentration in the serum of 
patients with schizophrenia. Procedia Chem 
2014;10:80-85.
46. Palomino A, González-Pinto A, Aldama A, et al. 
Decreased levels of plasma glutamate in patients 
with first-episode schizophrenia and bipolar 
disorder. Schizophr Res. 2007;95:174-178.
47. Anderson G, Maes M. Schizophrenia: linking 
prenatal infection to cytokines, the tryptophan 
catabolite (TRYCAT) pathway, NMDA 
receptor hypofunction, neurodevelopment and 
neuroprogression. Prog Neuropsychopharmacol 
Biol Psychiatry 2013;42:5-19.
48. Hashimoto K. Targeting of NMDA receptors in 
new treatments for schizophrenia. Expert Opin 
Ther Targets 2014;18:1049-63.

Chapter 7
General discussion
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The aim of this thesis was to investigate ways to evaluate psychotic disorders in individual 
patients across diagnostic boundaries, in a way that is applicable in everyday practice. In order 
to build upon available research, evaluation and classification by means of DSM-IV1 was also 
performed. Main findings are discussed below followed by a section with theoretical and clinical 
considerations. Finally, some limitations are mentioned to identify future research directions.
Main findings
Copy Number Variations (CNVs)
Routine screening for CNVs by means of micro-array was performed in 80 patients presenting 
with psychosis. Although in 3 out of 80 patients a CNV was found, i.e. 2 microduplications 
(1p13.3 and 7q11.21q11.22, respectively) and 1 microdeletion (1q21.1), these could not be 
related to the psychotic symptoms. From a clinical point of view, routine screening for CNVs 
in psychotic disorders seems to be of limited additional value.
It should be noted that targeted screening for CNVs can contribute to extension of 
knowledge about the genetic architecture predisposing for psychiatric and non-psychiatric 
disorders. Recent studies that appeared after publication of our results, showed that genetic 
polymorphisms at the 1p13.3 locus are associated with coronary artery disease.2 Since 2008 
deletions and duplications on 1q21.1 have been reported to be associated with a broad variety 
of neuropsychiatric and developmental disorders.3,4 Aberrations (though not duplications, 
as found in our patient) in the 7q11.21q11.23 region were reported to give rise to infantile 
spasms and pontocerebellar hypoplasia.5,6 Furthermore, studies into CNVs in both patients 
and controls show similar subtle cognitive defects related to microdeletions in 15q11.2.7 
These defects could possibly be generalized to the overall genetic basis of connectivity and 
information processing in the brain.8
For current clinical practice, these promising results stress the importance of careful 
evaluation of symptomatology, dysmorphic features, cognition, (childhood) development 
and family history, in order to search for chromosomal aberrations in a purposeful way. In 
specific cases, such as Prader-Willi syndrome or 22q11.2 deletion syndrome, identification of 
the genetic disorder is of great importance for adequate counselling and treatment of psychotic 
symptoms associated with the syndrome.
Cycloid psychoses according to Leonhard (LCP)
The term cycloid psychosis comprises acute and relapsing psychoses with a pleiomorphic 
symptom profile. Depending on the subtype, an intraphasic bipolarity can be observed 
consisting of severe anxiety or ecstasy, confusional states and psychomotor disturbances.9 
Outcome is usually favourable, with little to no residual symptomatology nor cognitive decline.10,11
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The concept of cycloid psychoses according to Leonhard (LCP) was investigated in a 
cohort of 80 patients admitted for treatment of psychoses by means of a checklist according 
to Leonhard’s original descriptions. A prevalence of ~15% was found, which is in line with 
previously reported prevalence rates of 8-24%.12,13 Symptomatic reduction was found to be 
greater in the LCP group as compared to the non-CP group.
In spite of the small patient sample, the three subtypes of LCP could be discriminated 
from other psychotic disorders by their specific symptomatology and intraphasic bipolarity. 
Key features of the core syndromes included pananxiety, perplexity, psychomotor disturbances, 
mood swings and hallucinatory experiences. 
Patients diagnosed with LCP were mostly classified as DSM Brief Psychotic Disorder (DSM-
BPD) or ICD Acute Polymorphic Psychotic Disorder (ICD-APP).14 The highest concordance 
rates were found for LCP and ICD-APP. A concordance rate of 0.63 (p<0.001) for LCP and the 
operational criteria as formulated by Perris and Brockington15 further illustrates that cycloid 
psychoses according to Leonhard are not sufficiently covered by current classification systems. 
Cycloid psychoses differ from schizophrenia and related disorders with respect to 
symptomatology, course and prognosis and it was advocated to acknowledge the cycloid 
psychoses as different from existing classification categories. Merely adding a diagnostic 
category should nonetheless never be the main objective of clinical research and in the acute 
phase, cycloid psychoses can indeed be treated effectively with antipsychotic agents. However, 
there is no evidence for long-term use of antipsychotic medication to prevent relapses, and 
most (though little) evidence points in the direction of mood stabilizers as the agents of choice 
in case of maintenance therapy.16 The possible influence on important treatment choices made 
in clinical practice illustrates the instrumental value of the cycloid psychoses. 
With respect to research into psychosis spectrum disorders, the cycloid psychoses 
might be a valuable counterpart for schizophrenia and related psychoses. The observed 
differences in clinical picture and treatment point in the direction of different neurobiological 
underpinnings, with cycloid psychoses as disorders in which neuroplasticity and connectivity 
might be better developed or preserved versus profound ‘disconnectivity’ in schizophrenia. 
This disconnectivity model probably exceeds the boundaries of current classification systems. 
Biochemical parameters 
The neurotrophic proteins Brain Derived Neurotrophic Factor (BDNF) and S100B were 
measured in the serum of 58 patients with psychotic disorders. It was found that BDNF was 
lowered in patients with an acute psychotic episode, irrespective of diagnostic category. It was 
concluded that BDNF can be regarded as a general marker for neuroplasticity in both psychotic 
and non-psychotic disorders. In the case of S100B, it was found that higher baseline levels 
corresponded with more negative symptoms after 6 weeks of treatment, which was in line 
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with other studies.17,18 Interestingly, it also appeared that lower baseline levels of S100B were 
associated with more positive symptoms after 6 weeks of treatment as compared to the other 
subgroups. Since S100B has both neurotoxic and neuroprotective effects, it was speculated 
that the elevated levels of S100B in this group might represent deficiencies in neuroprotective 
mechanisms in these patients. The findings should be regarded cautiously, since a study from 
Van der Leeuw et al. (GROUP) found no associations between serum S100B levels and illness 
parameters in patients with psychotic disorders.19 In contrast, a recent meta-analysis did 
establish relationships between S100B, illness duration and clinical symptoms in patients with 
schizophrenia.20 
It was hypothesized that subnormal levels of S100B might initially induce positive 
symptoms while during the course of disease S100B levels might rise, resulting in the 
development of negative symptoms due to a neurotoxic effect of the higher S100B levels in 
the brain. BDNF and S100B might be related to neuroplasticity and (dis)connectivity, maybe 
not individually, but as members from a network with other neurotrophic proteins interacting 
with each other.
Plasma levels of the main dopamine metabolite homovanillic acid (HVA) were measured 
in 58 psychotic patients.21 Overall baseline plasma HVA (pHVA) concentrations did not differ 
from a matched control sample and were not associated with treatment responsiveness of 
symptomatology, which was in line with other studies.22 However, after 6 weeks of treatment a 
larger decrease in pHVA concentrations was observed in patients with first episode psychosis 
(FEP) as compared to patients with relapsing or chronic psychoses. This larger decrease was 
significantly associated with better symptomatic improvement. Better treatment outcome in 
patients with FEP was previously reported by other investigators.23,24 
The observed differences between patients with FEP and those with relapsing or chronic 
psychoses could be related to the individual’s state of neuroplasticity, reflected by the ability to 
alter pHVA levels. Lack of plasticity is suggested to be related to loss of antipsychotic efficacy, 
poor prognosis and chronic course of disease.25,26 The same holds for the association between 
changes in plasma HVA levels and antipsychotic responsivity in other psychosis spectrum 
disorders such as bipolar disorder, schizoaffective disorder, and delusional disorder.27-30 These 
findings illustrate the importance of investigating psychoses across the boundaries of current 
classification systems. The model of neuroplasticity and (dis)connectivity might provide a more 
suitable framework for connecting clinical and biochemical aspects of psychotic disorders.
Biochemistry in cycloid psychoses 
Since LCP was considered a valuable counterpart for schizophrenia, the two disorders were 
investigated in order to establish whether the clinical differences, especially the absence of 
cognitive decline in LCP, were possibly associated with different biochemical underpinnings. 
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Next to dopamine, the glutamate system has been extensively investigated and it has become 
clear that disturbed glutamatergic neurotransmission is associated with negative symptoms 
and cognitive dysfunction via the NMDA receptor.31-33 Furthermore, earlier studies have 
shown beneficial effects of high dose (0.8mg/kg/day) glycine augmentation to antipsychotic 
treatment.34-36 Glycine is an essential co-agonist for the N-methyl-D-aspartate (NMDA) 
receptor.37
With respect to the dopamine metabolite HVA, no differences were found. Glutamate 
levels were elevated in both disorders. Levels of BDNF were lowered in patients with 
schizophrenia, but not with LCP, as compared to controls. In patients with LCP, elevated levels 
of glycine were found as compared to controls, patients with schizophrenia, and patients with 
other psychosis spectrum disorders. Since biochemical profiles in patients with LCP were, to 
date, not previously investigated, these findings could be of help in further understanding of 
the pathophysiology and treatment of LCP and other psychotic disorders.
The elevated levels of glycine in LCP might be explained as a compensatory reaction to 
the disturbed glutamatergic neurotransmission. This would suggest better neuroplasticity and 
connectivity in LCP as compared to schizophrenia, which is consistent with the finding of 
lowered levels of BDNF in schizophrenia and a more favourable prognosis for LCP. Differences 
in the extent of (dis)connectivity between LCP and other (schizophrenia-like) disorders could 
possibly contribute to understanding the common base of psychosis spectrum disorders.
Theoretical and clinical considerations
Chromosome aberrations, neurotrophic proteins and neurotransmitter metabolites could 
each be regarded as representatives of neuroconnectivity and -plasticity in psychosis spectrum 
disorders. The concept of LCP appears to differ from other psychotic disorders with respect to 
symptomatology and disease course, but also with respect to biochemical characteristics. They 
could therefore be of great heuristic value for understanding psychosis in general. Psychotic 
symptoms are highly prevalent and emerge in a broad variety of psychiatric disorders. In the 
spectrum of psychotic disorders, most research to date has focused on schizophrenia, but over 
the years it has become evident that there is a considerable overlap between schizophrenia 
and the other disorders in the spectrum, such as schizoaffective disorder, atypical psychoses, 
delusional disorder and bipolar manic psychosis.30,38-40 
Connectivity
The concept of (dis)connectivity has gained attention in the past years as being a possible 
common denominator in the etiology and pathophysiology of psychotic symptoms in a 
neurodevelopmental rather than in a neurodegenerative sense.41-44 Connectivity and synaptic 
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plasticity are related and appear to be key factors in brain development, maintenance and 
protection. 
The theory of physiological connectivity is as old as the 19th century.45 Subsequently, Karl 
Wernicke hypothesized that disturbed connection between the two language areas in the brain 
could result in aphasia (called conduction aphasia). He broadened this concept to psychiatric 
disorders and postulated that they emerged from disruptions of “psychischen Reflexbogen” 
which he called “sejunctions”.46 It should be noted that, at that time, schizophrenia had not 
been described as yet. When Kraepelin wrote about “dementia praecox”47, the young physician 
Otto Gross, who worked under direction of Eugen Bleuler, proposed that this concept was 
related to sejunction problems and coined the term “dementia sejunctiva”.48 Bleuler himself 
was an associationist thinker and tried to identify the fundamental psychological disorder in 
terms of problems in the relationship between ideas or concepts: “der Spaltung”, or in English 
“dissociation”.49 In summary, from a historical point of view, sejunction (connectivity) and 
dissociation (schizophrenia) have always been closely related.
Disconnectivity and psychosis
In the disconnection hypothesis, connection is referred to as functional rather than anatomical. 
It is proposed that psychiatric disorders are a result of disturbed functional connectivity in 
the adult developing brain. Several observations point especially in the direction of psychotic 
disorders such as schizophrenia.50,51 It was also suggested that psychosis is more likely to occur 
in the presence of both disconnection (white-matter lesions) and high DA levels, suggesting 
that psychosis is the result of faulty interplay between DA and reduced connectivity.52,53 
Taken together, the core pathology of psychoses can be considered as an impaired control of 
synaptic plasticity, manifesting as abnormal integration of neural systems, i.e. disconnectivity. 
This can be considered in line with the finding that in schizophrenia, reduced spine densities 
and smaller dendritic arbors are found postmortem.54,55 Pharmacological studies in healthy 
volunteers show that impairments of synaptic plasticity are consistent with schizophrenic 
symptoms, as was shown for NMDA-antagonists, D2-agonists, amphetamines and serotonin 
agonists.21,56,57
In patients with psychosis spectrum disorders, (psychopharmacological) treatment could 
be regarded as a way to “detach” from psychosis and to start re-establishing the cognitive and 
emotional interaction with the real world.58 In turn, this could lead to enhanced synaptic 
plasticity associated with reality.59 Investigating models for synaptic plasticity that can be 
evaluated in individual patients might be a useful and promising approach in the search for 
alternatives for diagnostic classification. Furthermore, it could facilitate genetic studies or have 
predictive value for pharmacological treatment.57
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Limitations and future directions
Limitations
Apart from a modest sample size which is inherent to this type of clinical investigation, several 
limitations can be discerned of which at least two should be mentioned here.
First of all, patients were assessed with rating scales that were originally designed for 
schizophrenia, thus collecting data about dimensions that could possibly not (all) be applied 
to non-schizophrenic psychoses or affective disorders with psychotic features. Affective 
symptoms therefore may have been underrepresented since the focus of most questionnaires 
(such as PANSS) is on overt positive symptomatology and negative symptoms. This stresses the 
importance of using both targeted and global/ extensive rating scales to tap detailed changes 
in the clinical picture of a patient as well as his subjective experience. Since treatment should 
essentially be directed towards functional recovery instead of symptomatic improvement only, 
such assessment strategies could be of value in future research.
Second, the heterogeneity of the sample with respect to diagnostic classifications, substance 
abuse, medication history and antipsychotic treatment could have influenced the results. 
Therefore, possible confounding effects were carefully evaluated in all analyses. Given the 
complex nature of psychosis spectrum disorders, certain to date unknown factors may have been 
overlooked. In order to certify clinical utility of our findings, it was decided to study psychoses 
across categorical diagnostic boundaries and to address this point in each relevant chapter.
Conclusion and future directions
The connectivity hypothesis provides a valuable framework to better understand psychosis 
spectrum disorders and exceeds the boundaries of current classification systems. In order 
to provide patients and clinicians with information applicable in everyday practice, research 
should not only focus on established diagnostic categories from existing classification systems, 
but should also broaden the scope to psychotic symptomatology across the boundaries of 
described syndromes. Efforts should be made to carefully describe symptomatology, illness 
severity and response to treatment. Subsequently, connectivity-related, measurable parameters 
(e.g. biochemical or genetic) could be used to identify new or establish existing subgroups 
of patients with specific characteristics or prognosis.60-62 The development of the Research 
Domain Criteria (RDoC) may facilitate this kind of research, by providing a framework 
for the integration of clinical and neurobiological parameters.63 This strategy may yield 
clinical syndromes (“exophenotypes”) or endophenotypes, which can be the focus of further 
investigation. But maybe even more importantly, patients might eventually be provided with 
better, personalized information on the nature and prognosis of their illness.
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The development of classification systems, of which the Diagnostic and Statistical Manual 
(DSM) is the most widely used and has worldwide been of great importance for psychiatry. 
The use of operational criteria to establish diagnoses has improved communication between 
psychiatrists and other (mental) health workers. Furthermore, by providing a nosological 
framework, it has promoted research into illness concepts. For patients, the establishment 
of certain diagnostic classes (e.g., post-traumatic stress disorder) has legitimated the burden 
of their mental problems by delineating these as a psychiatric disorder, herewith promoting 
proper use of mental health care facilities and/or social services. Also, evidence based 
treatment guidelines have been developed to improve efficacy of treatment and outcome of 
disease. Finally, in a domain as complex as psychiatry, a classification system may function as 
an easy accessible tool for those who deal with known, possible or probable mental disorders 
in other than health care settings, such as policemen, lawyers, politicians and welfare workers.
Most of the categorical labels from psychiatric classification systems such as DSM are delineated 
by means of consensus instead of a known etiology. This makes them mostly informative about 
clusters of symptoms at the time of establishing a “diagnosis”. However, diagnoses may alter 
during the course of the disease either because of their limited stability over time or change of 
definition of the diagnostic criteria in subsequent versions of the applied classification system. 
Albeit that many general risk factors for developing psychiatric disorders have been identified, 
longitudinal predictions for an individual patient are hard to establish. Psychiatrists generally 
accept that classification, though helpful in many ways, is not the same as diagnosing. Still, 
categorical diagnoses in psychiatry have become increasingly important not only for choosing 
the most appropriate treatment, but also for other purposes such as eligibility for social services 
avoiding imprisonment or for regulation (mental) health care costs.
The present thesis examined the utility of individualized diagnoses across diagnostic boundaries 
in patients with psychotic disorders, that are both informative and easily applicable in everyday 
practice. In all studies patients were therefore typically assessed by different diagnostic methods 
including also DSM or ICD in order to extend upon previous research.
Chapter 1 summarizes the way in which psychosis spectrum disorders are classified in DSM-5 
and addresses the pros and cons of classification. 
In chapter 2, it was investigated whether it would be valuable to perform routine screening for 
copy number variations (CNVs) in patients with psychosis spectrum disorders. Micro-array 
analysis was performed in 80 patients presenting with psychosis. 
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In 3 out of 80 patients a CNV was found (2 microduplications (1p13.3 and 7q11.21q11.22) 
and 1 microdeletion (1q21.1)). In none of the patients, these CNVs could be related to the 
psychotic symptoms. 
From a clinical point of view, routine screening for CNVs in psychosis spectrum disorders 
seems to be of limited additional value. However, the results stress the importance of careful 
evaluation of symptomatology, dysmorphic features, cognition, (childhood) development and 
family history, in order to search for chromosomal aberrations in a purposeful way. In specific 
cases, identification of the genetic disorder can be of great importance for counselling and 
treatment of psychotic symptoms associated with the syndrome.
Cycloid psychoses were described in the 1950s by Karl Leonhard, but are not included as 
such in the current classification systems. The term “cycloid psychosis” comprises acute and 
relapsing psychoses with a pleomorphic symptom profile that shows an intraphasic bipolarity 
(subtypes anxiety-happiness psychosis, confusion psychosis and motility psychosis). Prognosis 
is usually favourable and without cognitive decline and there is no evidence for long-term use 
of antipsychotic medication to prevent relapses. 
In chapter 3, the concept of cycloid psychoses according to Leonhard (LCP) was 
investigated in a cohort of 80 patients admitted for treatment of psychoses by means of a 
checklist according to Leonhard’s original descriptions. Objectives were to estimate the 
prevalence of LCP, to identify the discriminating symptoms and to calculate concordance with 
established diagnostic categories from DSM and ICD.
A prevalence of ~15% was found, which is in line with previously reported prevalence 
rates of 8-24%. Symptomatic reduction was found to be greater in the LCP group as compared 
to the non-CP group. Key features of the core syndromes (subtypes) included pananxiety, 
perplexity, psychomotor disturbances, mood swings and hallucinatory experiences. Patients 
diagnosed with LCP were mostly classified as DSM Brief Psychotic Disorder (DSM-BPD) or 
ICD Acute Polymorphic Psychotic Disorder (ICD-APP), with low concordance rates (Κ 0.35 
and 0.58, respectively (p≤0.001)). A concordance rate of 0.63 (p<0.001) was calculated for LCP 
and the operational criteria as formulated by Perris and Brockington.
It was concluded that cycloid psychoses according to Leonhard are not sufficiently 
covered by current classification systems. The possible, but relevant influence on treatment 
choices made in clinical practice illustrates the instrumental value of the cycloid psychoses. 
With respect to research into psychosis spectrum disorders, the cycloid psychoses might be a 
valuable counterpart for schizophrenia and related psychoses.
The next part of the thesis comprises studies into peripheral biochemical parameters in patients 
with psychosis spectrum disorders.
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Neurotrophic proteins are involved in the development, maintenance and survival of 
the central nervous system (CNS) and can be measured in peripheral blood. It is known that 
disturbances in the CNS can lead to the development of psychosis and vice versa. 
In chapter 4, the neurotrophic proteins Brain Derived Neurotrophic Factor (BDNF) 
and S100B were measured in the serum of 58 patients with psychosis spectrum disorders at 
baseline and after 6 weeks of treatment. Symptomatology and disease severity were assessed by 
means of CASH, PANSS and CGI.
It was found that BDNF was lowered in patients with an acute psychotic episode 
irrespective of diagnostic category, as compared to controls (20.3 ± 6.6 versus 24.4 ± 6.7 µg/l, 
p≤0.001). It was concluded that BDNF can be regarded as a general marker for neuroplasticity 
in both psychotic and other psychiatric disorders.
In the case of S100B, it was found that higher baseline levels (0.107 ± 0.030 µg/l) 
corresponded with more negative symptoms after 6 weeks of treatment, which was in line with 
other studies. Interestingly, it also appeared that lower baseline levels of S100B (0.034 ± 0.005 
µg/l) were associated with more positive symptoms after 6 weeks of treatment as compared 
to the other subgroups. Since S100B has both neurotoxic and neuroprotective effects, it was 
speculated that the lowered levels of S100B in this group might represent deficiencies in neuro-
protective mechanisms in these patients. 
The hypothesis was formulated that subnormal levels of S100B might initially induce 
positive symptoms while during the course of disease S100B levels might rise. This could in 
turn result in the development of negative symptoms due to a neurotoxic effect of the higher 
S100B levels in the brain. 
BDNF and S100B might be related to neuroplasticity and (dis)connectivity, maybe not 
individually, but as members from a network with other neurotrophic proteins interacting 
with each other.
The neurotransmitter dopamine plays an important role in the pathophysiology of psychoses. 
Homovanillic acid (HVA) is the main metabolite of dopamine. In chapter 5, plasma levels of 
HVA (pHVA) were measured in 58 patients admitted for treatment of psychosis spectrum 
disorders. Biochemical and clinical assessments (by means of CASH, PANSS and CGI) were 
done at baseline and after 6 weeks of treatment.
Mean baseline plasma HVA (pHVA) concentrations did not differ from a matched 
control sample (53.4 ± 13.7 nmol/l) and were not associated with treatment responsiveness of 
symptomatology, which was in line with other studies. However, after 6 weeks of treatment a 
larger decrease in pHVA concentrations was observed in patients with first episode psychosis 
(FEP) as compared to patients with relapsing or chronic psychoses (-20.7 ± 22.9 versus -4.9 ± 
23.1 nmol/l, respectively (p<0.05)). This larger decrease was significantly associated with better 
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symptomatic improvement. Better treatment outcome in patients with FEP was previously 
reported by other investigators. 
The observed differences between patients with FEP and those with relapsing or chronic 
psychoses could be related to the individual’s state of neuroplasticity, reflected by the extent to 
which pHVA levels change during treatment. 
Since LCP (from chapter 3) was considered a valuable counterpart for schizophrenia, in 
chapter 6, the two disorders were investigated in order to establish whether the clinical 
differences, especially the absence of cognitive decline in LCP, were possibly associated with 
different biochemical underpinnings. 
Besides dopamine, the glutamate system has gained special attention, since it has become 
clear that disturbances in glutamatergic neurotransmission are associated with negative 
symptoms and cognitive dysfunction via the N-methyl-D-aspartate (NMDA) receptor. Glycine 
is an essential co-agonist for the NMDA receptor.
The study group consisted of 33 patients with schizophrenia and 10 patients with LCP, 
who were assessed by venipuncture and rating scales according to the same methods as in 
chapter 4 and 5. For diagnoses of LCP, the checklist from chapter 3 was used. 
Symptomatic reduction was the largest in patients with LCP. With respect to HVA, no 
differences were found. Glutamate levels were elevated in both disorders as compared to 
controls. Serum levels of BDNF were lowered in patients with schizophrenia, but not with 
LCP, as compared to controls. In patients with LCP, elevated levels of glycine were found 
as compared to controls, patients with schizophrenia, and 15 patients with other psychosis 
spectrum disorders. 
The elevated levels of glycine in LCP were explained as a compensatory reaction to 
the disturbed glutamatergic neurotransmission that patients with schizophrenia and other 
psychoses might not be able to. It could imply better neuroplasticity and connectivity in LCP 
as compared to schizophrenia. This would be consistent with the finding of lowered levels of 
BDNF in schizophrenia and the more favourable prognosis for LCP. 
Since biochemical profiles in patients with LCP were, to date, not previously investigated, 
these findings could be of help in further understanding of the pathophysiology and treatment 
of psychosis spectrum disorders. Differences in the extent of (dis)connectivity between LCP 
and other (schizophrenia-like) disorders could possibly contribute to a better understanding 
of the common neurobiological base of psychosis spectrum disorders.
In chapter 7, results are summarized and discussed. Theoretical and clinical considerations are 
made with respect to the concept of neuroconnectivity as common denominator in psychosis 
spectrum disorders. 
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Samenvatting / summary in Dutch
De ontwikkeling van classificatiesystemen binnen de psychiatrie, waarvan de Diagnostic 
and Statistic Manual for Psychiatric Disorders (“de DSM”) de bekendste en meest gebruikte 
is, heeft wereldwijd een belangrijke invloed gehad op veel aspecten van het vakgebied. Het 
gebruik van eenduidige operationele criteria om een classificerende diagnose te stellen heeft de 
communicatie tussen psychiaters onderling verbeterd, evenals die met andere professionals in de 
(geestelijke) gezondheidszorg. Daarnaast heeft het beschikbaar zijn van een gemeenschappelijk 
nosologisch raamwerk het wetenschappelijk onderzoek naar de beschreven ziekteconcepten 
bevorderd. Voorts betekende de invoering van bepaalde diagnostische classificaties (zoals de 
posttraumatische stress-stoornis) voor veel patiënten een rechtvaardiging van hun psychische 
problemen, doordat deze erkend werden als psychiatrische stoornis. Voor velen van hen werd 
het hierdoor mogelijk om gebruik te maken van (geestelijke) gezondheidszorg en/of sociale 
voorzieningen. Op basis van de uitkomsten van wetenschappelijk onderzoek konden algemene 
behandelrichtlijnen worden ontwikkeld, waarmee de uniformiteit, effectiviteit en uitkomsten 
van behandelingen verbeterd werden. Tot slot is een classificatiesysteem, zeker in een complex 
domein zoals de psychiatrie, een eenvoudig toegankelijk instrument voor hen die te maken 
krijgen met bekende, mogelijke of waarschijnlijke psychiatrische stoornissen op plaatsen 
buiten de gezondheidszorg, zoals politie, justitie, politiek en sociale diensten. 
De meeste labels in een classificatiesysteem zoals de DSM zijn categorieën die middels 
consensus zijn vastgesteld. Ze zijn veelal niet gebaseerd op een bekende oorzaak en geven 
hoofdzakelijk informatie over symptoomclusters ten tijde van het stellen van de “diagnose”. 
Diagnoses kunnen veranderen gedurende het ziektebeloop vanwege de beperkte diagnostische 
stabiliteit, maar ook doordat de diagnostische criteria veranderen in een volgende versie van 
het classificatiesysteem. Daarnaast blijft het, ondanks het feit dat veel algemene en specifieke 
aspecten van psychiatrische stoornissen bekend zijn, bijzonder moeilijk om een individuele 
patiënt duidelijkheid te geven over wat hij of zij kan verwachten op de korte of langere termijn. 
Psychiaters zijn zich er in het algemeen van bewust dat classificatie behulpzaam is, maar 
niet hetzelfde is als het stellen van een diagnose met bekende oorzaak/ontstaanswijze. In de 
loop der jaren is echter in toenemende mate nadruk komen te liggen op die “diagnostische” 
classificaties, niet alleen om een behandeling te kiezen, maar ook om bijvoorbeeld te bepalen of 
iemand aanspraak kan maken op sociale voorzieningen, of iemand veroordeeld wordt tot een 
gevangenisstraf en ook om (geestelijke) gezondheidszorgkosten te reguleren.
Dit proefschrift gaat over psychotische stoornissen. De studies in dit proefschrift hadden als 
doel om de bruikbaarheid te onderzoeken van geïndividualiseerde diagnoses bij patiënten met 
een psychotische stoornis, dóór de categorale diagnostische grenzen heen en op een manier die 
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zowel informatief is als ook eenvoudig toepasbaar in de dagelijkse praktijk. In elke studie werden 
patiënten op één zo’n manier onderzocht. Om aan te sluiten bij het bestaande onderzoek, werden 
patiënten ook ingedeeld conform een bekend classificatiesysteem (DSM of ICD). 
In hoofdstuk 1 wordt een overzicht gegeven van de wijze waarop psychotische stoornissen in 
de DSM worden ingedeeld en wordt ingegaan op de voors en tegens van classificatie. 
In hoofdstuk 2 werd onderzocht of het zinvol kan zijn om patiënten met een psychose routinematige 
te screenen op zogenoemde copy number variations (CNVs; bepaalde zéér kleine chromosomale 
afwijkingen). Hiertoe werd een micro-array verricht bij 80 patiënten die in ons psychiatrische 
ziekenhuis werden behandeld vanwege een psychose. Bij 3 van de 80 patiënten werd een CNV 
gevonden (2 microduplicaties (1p13.3 en 7q11.21q11.22) en 1 microdeletie (1q21.1)). Deze konden 
evenwel bij geen van de patiënten worden gerelateerd aan de psychotische symptomen. 
Vanuit klinisch oogpunt lijkt het routinematig screenen op CNVs bij psychotische 
stoornissen van weinig toegevoegde waarde. Het is in de dagelijkse praktijk evenwel van groot 
belang om een zorgvuldige evaluatie te verrichten van symptomatologie, dysmorfe kenmerken, 
cognitieve stoornissen en (vroegkinderlijke) ontwikkelings- en familieanamnese. Op die 
manier kan op gerichte wijze worden gezocht naar aanwijzingen voor eventuele chromosomale 
afwijkingen. Het is van belang om genetische syndromen te identificeren, teneinde adequate 
voor lichting te kunnen geven en (psychotische) symptomen die gepaard gaan met het 
syndroom op de juiste manier te behandelen.
De cycloïde psychose werd in de jaren ’50 van de vorige eeuw beschreven door Karl Leonhard, 
maar komt als zodanig in de huidige classificatiesystemen niet voor. De term “cycloïde psychose” 
slaat op acute en recidiverende psychoses met een veelzijdig symptoomprofiel, dat binnen de 
psychotische fase snel kan wisselen tussen 2 extreme polen (zoals angst en gelukzaligheid). De 
prognose is doorgaans gunstig, zonder cognitief verval en er is geen bewijs voor een langdurige 
onderhoudsbehandeling met antipsychotica om recidieven te voorkomen. 
In hoofdstuk 3 werd onderzocht of het van waarde zou kunnen zijn om in de praktijk te 
werken met concept van de cycloïde psychose. Hierbij waren de vragen: 1. hoe vaak de cycloïde 
psychose voorkomt, 2. wat de symptomen zijn die de cycloïde psychose onderscheiden van 
andere psychotische stoornissen en 3. in welke bestaande diagnostische categorieën patiënten 
met een cycloïde psychose worden ingedeeld. Om de diagnose cycloïde psychose conform 
de beschrijvingen van Leonhard (LCP) te stellen werd gebruik gemaakt van een checklist 
gebaseerd op die originele beschrijvingen. De studiegroep bestond uit 80 patiënten die waren 
opgenomen voor de behandeling van een psychose. 
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Bij 12 van de 80 patiënten werd de diagnose LCP gesteld, wat neerkomt op een prevalentie 
van ~15%. Dit getal is in overeenstemming met eerder gerapporteerde prevalentiecijfers van 
8-24%. De symptomatische verbetering was groter in de LCP-groep dan in de non-CP groep. 
De belangrijkste onderscheidende symptomen van LCP waren allesoverheersende angst, 
verbijstering, psychomotore stoornissen, stemmingswisselingen en hallucinatoire belevingen. 
Patiënten met LCP werden het vaakst geclassificeerd als Kortdurende Psychotische Stoornis 
conform DSM-IV (DSM-PBD) of Acute Polymorfe Psychotische Stoornis conform ICD-10 
(ICD-APP), waarbij de concordantie laag was (Κ respectievelijk 0.35 en 0.58, p≤0.01). De 
concordantie van LCP met de set bestaande set operationele criteria zoals geformuleerd door 
Perris en Brockington was 0.63 (p<0.001).
Er werd geconcludeerd dat de cycloïde psychosen (LCP) niet adequaat zijn geïncorporeerd 
in de huidige classificatiesystemen. Vanwege de directe invloed op de keuze van een 
(onderhouds)behandeling lijken de cycloïde psychosen echter wel relevant voor de praktijk 
en zou het wenselijk zijn om ze als zodanig op te nemen in volgende versies van de bestaande 
classificatiesystemen. In het wetenschappelijk onderzoek naar psychosespectrumstoornissen 
zouden de cycloïde psychosen een waardevolle aanvulling op het spectrum van schizofrenie en 
schizofrenie-achtige psychoses kunnen zijn. 
Zijn er stoffen in het bloed die patiënt en behandelaar informatie kunnen geven over sympto-
matologie, behandelbaarheid of prognose? Deze vragen werden behandeld in de volgende 
hoofdstukken.
Neurotrofe eiwitten zijn stoffen die betrokken zijn bij de aanleg, onderhoud en herstel, ook 
wel genoemd “plasticiteit”, van het centraal zenuwstelsel (CZS). Sommige van deze eiwitten 
kunnen betrouwbaar in het bloed worden bepaald. Het is bekend dat verstoringen in het CZS 
aanleiding kunnen geven tot psychoses en vice versa. 
In hoofdstuk 4 werden de neurotrofe eiwitten Brain Derived Neurotrophic Factor (BDNF) 
en S100B gemeten in het serum van 58 patiënten met een psychotische stoornis. De metingen 
werden verricht bij aanvang van behandeling en na 6 weken behandeling met antipsychotica. 
Tevens werden de symptomen en de ernst van de psychose gemeten met behulp van 
vragenlijsten.
Er werd gevonden dat de BDNF-concentraties verlaagd waren bij patiënten met een 
psychose ten opzichte van een controlegroep (20.3 ± 6.6 versus 24.4 ± 6.7 μg/l, p≤0.001), 
ongeacht de diagnostische categorie waar de patiënten waren ingedeeld. Er werd geconcludeerd 
dat BDNF beschouwd kan worden als een algemene marker voor neuroplasticiteit in zowel 
psychotische als niet-psychotische stoornissen. 
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Met betrekking tot S100B werd gevonden dat hogere concentraties bij aanvang van 
de behandeling (0.107 ± 0.030 μg/l) correspondeerden met meer zogeheten “negatieve 
symptomen” na 6 weken behandeling, hetgeen in andere onderzoeken eerder ook werd 
gevonden. Interessant genoeg bleek eveneens dat verlaagde S100B-concentraties bij aanvang 
(0.034 ± 0.005 μg/l), geassocieerd waren met meer zogenaamde “positieve symptomen” na 6 
weken behandeling. Omdat S100B zowel een neurotoxische als een neuroprotectieve werking 
heeft, die afhangt van de concentratie, werd gespeculeerd dat de verlaagde concentraties in 
deze groep wellicht wijzen op tekorten in de neuroprotectieve mechanismen bij deze patiënten. 
De hypothese werd geformuleerd dat verlaagde concentraties van S100B in het begin 
leiden tot positieve symptomen, waarna gedurende het ziektebeloop de S100B-concentraties 
juist stijgen. Dat zou op zijn beurt weer leiden tot het ontstaan van negatieve symptomen door 
ofwel het neurotoxisch effect van de hoge S100B-concentratie ofwel als reactie op door de 
psychose aangerichte schade in het brein. Dat zou echter verder onderzocht moeten worden.
BDNF en S100B zijn waarschijnlijk beide gerelateerd aan neuroplasticiteit en (dis)
connectiviteit, wellicht niet individueel, maar als onderdelen van een netwerk van neurotrofe 
factoren die met elkaar interacteren.
De neurotransmitter dopamine speelt een voorname rol bij het ontstaan van psychoses. 
Homovanillinezuur (HVA) is de belangrijkste metaboliet van dopamine. In hoofdstuk 5 
werden de plasmaconcentraties van HVA (pHVA) gemeten bij 58 patiënten die waren opge-
nomen voor de behandeling van een psychotische stoornis. De metingen werden verricht bij 
aanvang en na 6 weken behandeling en op die momenten werd tevens de symptomatologie en 
ernst van de psychose gemeten met vragenlijsten. 
De gemiddelde pHVA van de patiënten verschilde niet van een controlegroep (53.4 ± 13.7 
nmol/l). Er kon geen verband worden gelegd tussen pHVA en bepaalde symptomen of respons 
op behandeling, hetgeen door andere onderzoekers eerder ook werd gevonden. 
Na 6 weken behandeling werd echter een grotere afname van de pHVA gemeten bij 
patiënten met een eerste psychotische episode (first episode psychosis; FEP) in vergelijking 
met patiënten met een recidief of chronische psychose (respectievelijk -20.7 ± 22.9 versus -4.9 
± 23.1 nmol/l, p<0.05). Deze sterkere afname was significant geassocieerd met een grotere 
verbetering van de psychotische symptomen. Betere behandeluitkomsten bij patiënten met 
FEP werden al eerder beschreven in andere studies. 
Het lijkt erop dat patiënten met een eerste psychose beter in staat zijn om de verstoringen 
in het CZS te herstellen dan patiënten met een chronische of recidiverende psychotische 
stoornis. Deze verschillen zouden verband kunnen houden met de mate van neuroplasticiteit 
in het individu, weergegeven als de mate waarin de pHVA verandert tijdens behandeling. 
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Omdat LCP in hoofdstuk 3 werd aangemerkt als mogelijk waardevolle aanvulling op het schizo-
frenie-spectrum, werden in hoofdstuk 6 beide stoornissen rechtstreeks met elkaar vergeleken. 
De vraag was of de verschillen in klinisch beeld en prognose (in het bijzonder de afwezigheid 
van cognitief verval bij LCP) mogelijk verklaard kunnen worden vanuit verschillen in het 
onderliggend biochemisch profiel. 
Naast dopamine en neurotrofe eiwitten werd in de biochemische analyse aandacht besteed 
aan het glutamaterge systeem, omdat uit onderzoek duidelijk is geworden dat een verstoring in 
de glutamaterge neurotransmissie verband houdt met het ontstaan van negatieve symptomen 
en cognitieve dysfunctie via de N-methyl-D-aspartaat (NMDA) receptor. De stof glycine is een 
essentiële co-agonist voor de NMDA-receptor. In dit onderzoek werden 10 patiënten met LCP en 
33 patiënten met DSM-schizofrenie onderzocht middels bloedafname en vragenlijsten conform 
de werkwijze in hoofdstuk 4 en 5. Voor de diagnose LCP werd checklist uit hoofdstuk 3 gebruikt.
De symptomatische verbetering was het grootst in de LCP-groep. Er werden geen 
verschillen tussen de groepen gevonden met betrekking tot de concentraties van HVA. De 
glutamaatconcentraties waren verhoogd bij beide stoornissen ten opzichte van gezonde 
controles. De serumconcentraties van BDNF waren verlaagd bij patiënten met schizofrenie, 
maar niet met LCP, in vergelijking met controles. Bij patiënten met LCP werden verhoogde 
concentraties van glycine gevonden in vergelijking met zowel de controles, de patiënten met 
schizofrenie én 15 patiënten met andere psychosespectrumstoornissen. 
Het verhoogde glycine bij LCP werd uitgelegd als een compensatoire reactie op de 
verstoorde glutamaterge neurotransmissie, waartoe de patiënten met schizofrenie of andere 
psychotische stoornissen niet in staat zouden zijn. Dit zou betekenen dat de neuroplasticiteit 
en connectiviteit bij LCP beter zijn dan bij schizofrenie. Hierbij past het gevonden verschil in 
BDNF-concentraties, die bij schizofrenie (maar niet bij LCP) lager zijn dan bij controles. Ook 
de betere prognose van LCP past bij deze bevindingen. 
Omdat de biochemische profielen van patiënten met LCP tot op heden niet eerder 
werden onderzocht, kunnen deze uitkomsten behulpzaam zijn bij het verder begrijpen van de 
pathofysiologie en behandeling van psychotische stoornissen. Verschillen in de omvang van 
de (dys)connectiviteit tussen LCP en andere (schizofrenie-achtige) stoornissen kan mogelijk 
bijdragen aan het beter begrijpen van de gemeenschappelijke neurobiologische basis van 
psychosespectrumstoornissen. 
In hoofdstuk 7 worden de belangrijkste resultaten samengevat en bediscussieerd en worden 
theoretische en klinische overwegingen gemaakt met betrekking tot het concept van neuro-
connectiviteit als grote gemene deler bij psychosespectrumstoornissen. 
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